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SUMMARY
Since Beatson demonstrated in 1896 that castration 
resulted in shrinkage of breast tumours in approximately 
30% of women thus treated, it has been shown that 
oestradiol is a trophic hormone for certain types of 
mammary cancer. Recent evidence suggests that the 
mitogenic effects of oestradiol are mediated by the 
stimulatory growth factors IGF-I and TGF-ce, acting in a 
way like second messengers. This is consistent with the 
autocrine growth hypothesis proposed by Sporn and Todaro, 
in which tumour cells produce mitogenic polypeptides to 
which they can respond via specific cell surface 
receptors. Additional evidence indicates that the 
cytostatic effects of the anti-oestrogenic compound 
tamoxifen may be mediated by secretion of TGF-B by ER 
positive human breast cancer cells, in an autoinhibitory 
loop.
In this thesis it has been shown that TGF-p (50 pM) has a 
significant cytostatic effect on ER positive human breast 
carcinoma cells (the ZR-75 cell line). Similarly, 
treatment with a-IF (500iu /ml) has an anti-proliferative 
effect. The duration of the cytostatic effect for TGF-p 
and a-IF was related to the duration of exposure to each 
of these agents.
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When they were removed from the cell culture medium, the 
breast cancer cells started to regrow after a lag period 
of approximately 24 hours, parallel to control cultures. 
a-IF reduced expression of ER protein to 40% of control, 
untreated values, and again this effect was maintained for 
the duration of exposure to a-IF. After a lag phase of 24 
hours, a-IF induced a rise in TGF-p mRNA by some 8 fold 
relative to untreated cells and a reduction in ER mRNA to 
approximately 50% of control. The kinetics of induction 
of TGF-p mRNA were similar to the antiproliferative effect 
of a-IF in that there was an initial lag phase, the 
duration of cytostasis was proportional to the duration of 
exposure of a-IF and when a-IF was removed from the 
medium, the cells started to regrow and TGF-p mRNA levels 
return to unstimulated values after a short delay.
Nuclear run on assays showed that the increase in TGF-p 
mRNA concentration was due to an increase in its 
transcriptional rate.
Using a bioassay for TGF-p, which was related to its dose- 
dependent inhibition of JH-thymidine incorporation by 
mink lung epithelial cells, it was shown that a 
commercially available anti-TGF-B polyclonal antibody 
could neutralise the effects of TGF-B (50jttg of antibody 
neutralised lng of TGF-p in the assay.) Coincubation of 
ZR-75 cells with a-IF and the anti-TGF-p antibody reduced 
the cytostatic effect of a-IF by 60%.
19
Cell binding studies with radio-iodinated TGF-p revealed 
that the ZR-75 cells have 5,800 high affinity binding 
sites with a dissociation constant of 70 pM.
Oncogene transfection of c-myc and activated H-ras 
oncogenes into mink lung epithelial cells revealed that 
this altered the response of the cells to exogenous growth 
factors. C-myc transfection reduced the response 
(^H-thymidine incorporation) to TGF-p but enhanced the 
normal stimulatory response to EGF. Activated H-ras 
transfection abolished the response of the epithelial 
cells to both TGF-p and EGF.
Taking these results in concert, it would appear that a 
significant proportion of the cytostatic effect of a-IF is 
mediated by TGF-p in this human breast cancer cell line. 
Growth factor responsiveness can be altered by oncogene 
transfection and the presence of other growth factors in 
the microenvironment. This could be relevant to the 
process of promotion during epithelial carcinogenesis.
20
CHAPTER I
INTRODUCTION
21
SECTION 1.1 EPIDEMIOLOGY OF BREAST CANCER
Breast cancer is the most common form of all malignant 
diseases in women, with an annual incidence of 21,000 new 
cases in England and Wales and 100,000 new cases in the 
United States. It is therefore a relatively common cause 
of mortality and morbidity in the Western world.
There are a number of known aetiological factors (1). 
Linked, reproductive variables which increase the risk of 
developing the disease include early menarche and late 
menopause. First childbirth over the age of 30 years 
increases breast cancer risk threefold, relative to women 
who have their first child before the age of twenty. Pre­
existing benign breast disease such as hyperplastic cystic 
mastopathy contributes to breast cancer risk. There is 
also a familial component in that first degree relatives 
of breast cancer patients are 2-3 times more likely to 
develop the disease compared to controls. Obese women, 
probably through increased aromatisation of steroid 
hormones in adipose tissue, have a small but significantly 
increased risk of breast cancer.
In view of the endocrine implications of these risk 
factors, there is a vast literature attempting to 
correlate plasma and tissue hormone concentrations to the 
risk of developing breast cancer.
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Total plasma oestradiol levels do not predict breast 
cancer risk in pre or post menopausal women (2). However, 
recent reports from a large, prospective epidemiological 
trial based in Guernsey have indicated that if corrections 
are made for the extent of oestradiol bound to sex hormone 
binding globulin, the concentration of free oestradiol was 
significantly elevated in those patients who subsequently 
developed interval breast cancers (3). These data are 
consistent with a model of breast carcinogenesis which 
postulates that cancer risk is a function of "biological 
breast age" which integrates the duration and degree of 
exposure of mammary tissue to "active oestrogen" (4).
It is possible to use the framework of epidemiological 
data to generate a testable, stochastic laboratory model 
of mammary carcinogenesis. According to current 
hypotheses, carcinogenesis is a multi-stage process; the 
first stage, initiation, is induced by mutagens (e.g. 
carcinogenic chemicals,radiation and viruses) and is 
irreversible; the second stage, promotion, can be brought 
about by agents such as hormones (steroids and 
polypeptides), phorbol esters and some viruses; the third 
stage, progression, is characterised by the development of 
heterogeneity within tumours. Again, the literature in 
the field of mammary carcinogenesis is vast, but in 
summary, laboratory studies in vitro and in vivo in mice 
suggest that oestrogen (in its various forms) is a weak 
genotoxic agent at physiological concentrations.
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Oestrogen is unlikely to be responsible for initiation 
(5). In contrast, promotion of human breast tumour cell 
growth is well-recognised to be oestrogen dependent in 
vitro (6) and in vivo (7) using murine and human tumour 
model systems.
The hormonal responsiveness of breast tumours is mediated 
primarily by the oestrogen receptor (ER); a 66-kilodalton 
protein consisting of a central DNA binding domain, a 
carboxy-terminal oestrogen-binding domain and an amino- 
terminal oestrogen "modulating" domain. Cloning of the ER 
and mutational analysis studies have allowed regional 
mapping and definition of the function of the various 
sectors of the molecule. Binding of oestrogen to its 
receptor, which resides predominately within the nucleus 
of target cells (8), increases the affinity of the 
hormone-receptor complex for the hormone responsive genes 
which are the targets for activated receptor. Electron 
microscopy has suggested that DNA-bound receptor dimers 
undergo cooperative binding thereby linking these distant 
hormone responsive elements to form DNA loops which may 
then participate in interactions between other trans­
acting transcriptional enhancers and gene promoters 
(9,10). The mRNA.species which are induced by hormone- 
receptor-DNA interaction are incompletely characterised 
and the function of their protein products is obscure, but 
is an active area of current research.
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Estimation of ER concentration in breast tumour specimens 
gives clinically useful information. Much of the early 
work was bedevilled by interpretative problems due to 
interlaboratory variation in assay procedure, but with 
international agreement on standards and improved 
protocols for specimen handling and processing, these 
problems have been largely overcome. The traditional 
assay for ER estimation is based on radioligand binding of 
3H-oestrodiol. However, this correlates well with newer 
methods such as immunocytochemical stains for ER,which 
gives an idea of heterogeneity of the ER tissue 
distribution (11).
Primary breast tumours are more commonly ER positive 
(i.e. greater than lOfmol receptor/mg protein) in post 
menopausal patients (60%) compared to premenopausal women 
(30%) . ER positive tumours tend to be well 
differentiated, exhibit lower DNA ploidy and lower 
proliferative rates (as assessed by flow cytometric 
estimation of S-phase fraction), than ER negative tumours 
(12, 13, 14) .
ER concentration gives valuable prognostic, information in 
that there is an improved overall survival from ER 
positive breast cancer (15), which has a prediliction for 
metastasising to bone, and is inversely correlated with 
the development of disease in liver and brain (16).
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ER status also helps therapeutic decisions; liver 
metastases tend to be unresponsive to hormonal 
manipulation regardless of ER status, while "relatively 
hormone responsive" sites of disease include bone, soft 
tissue and pleura; responses (i.e. tumour shrinkage) to 
hormonal manipulation are seen in up to 70% of ER positive 
patients (17).
Sir George Beatson was the first to show, in 1896, that 
removal of the ovaries could cause regression of breast 
cancer, in about 30% of all women thus treated. This was 
the original basis for the notion that oestrogens were 
trophic for certain breast tumours. A variety of hormonal 
therapies have been utilised over the past decades, but 
anti-oestrogens, aromatase inhibitors (which prevent 
synthesis of oestrogen and its metabolites) and 
progestational agents have emerged as the dominant 
therapeutic modalities (18). The molecular mechanism of 
action of those agents will be discussed later.
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SECTION 1.2 CURRENT HYPOTHESES ON AUTOCRINE / PARACRINE
CONTROL OF BREAST CANCER CELL PROLIFERATION
Growth of normal cells is controlled largely by the 
interplay between polypeptide hormones and hormone-like 
growth factors present in tissue fluids. In general, 
malignant cells require less of these exogenous growth 
factors than normal cells for optimal growth. Sporn and 
TodtLro (19) postulated that the malignant transformation 
of cells may be mediated by the release of polypeptide 
growth factors. A growth-promoting transforming 
polypeptide should have the following properties; it 
should be a strong mitogen and cause loss of density- 
dependent inhibition of growth in culture; it should cause 
morphological transformation of cells; it should cause 
anchorage independent growth. Such factors have been 
isolated and Sporn and Todaro coined the terms of 
autocrine and paracrine growth control. Autocrine control 
(fig 1) implies that the tumour cell produces polypeptide 
growth factors which bind to cell surface receptors on the 
same cell, autostimulating the tumour cell to grow. 
Paracrine growth control (fig 1) is exerted by release of 
polypeptides into the local environment and can interact, 
again via cell surface receptors, with adjacent cells, 
perhaps mediating a tumour/stromal cell interaction. 
Several oestrogen dependent breast cancer cell lines such 
as MCF-7 and ZR-75 have been isolated from patients with 
metastatic breast cancer.
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In vitro, the growth of these lines is stimulated by the 
addition of oestrogen and the formation of tumours 
following innoculation of MCF-7 cells into athymic, nude 
mice, is absolutely oestrogen dependent (20-24). Lippman 
and coworkers (25, 26) have presented evidence that 
"growth factor activities," some of which were oestrogen- 
induced, are released by these cell lines into serum-free 
conditioned medium. Subsequently they identified three of 
these factors as being transforming growth factor-ce 
(TGF-ce) , insulin like growth factor I (IGF-I) and platelet 
derived growth factor (PDGF). MCF-7 cells have receptors 
for.epidermal growth factor (EGF)(to which TGF-ce binds) 
and IGF-I receptors but not PDGF-receptors (although these 
receptors have been demonstrated on breast stromal cells 
(27)). On the basis of this information these authors 
proposed autocrine growth stimulation of MCF-7 cells in 
vitro, with the polypeptides acting in a way like second 
messengers following exposure to oestrogen (summarised in 
fig 1).
Further studies were performed to determine if these 
oestrogen induced growth factors in conditioned medium 
were capable of replacing oestrogen itself in induction of 
tumour formation by MCF-7 cells in vivo in the nude mouse. 
Dickson et al (25), demonstrated that the oestrogen 
conditioned medium, administered by mini-pumps, stimulated 
the development of MCF-7 cell implants into tumours grown 
in ovariectomised athymic mice.
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Conditioned medium from cells grown in the absence of 
oestrogen had no such effect. No stimulation of uterine 
wet weight was noted in either set of experiments which 
implies that the effect was independent of oestrogen.
While early tumour development was indistinguishable under 
oestrogen and oestrogen conditioned medium stimulation, 
the conditioned medium stimulated tumours were not capable 
of growth beyond approximately 0.5 cm in diameter. MCF-7 
cells secrete other proteins, including proteases and 
angiogenic substances into their microenvironment 
following oestrogen exposure. Clearly these factors could 
be important in promoting tumour growth in vivo, but could 
have been absent from the conditioned medium infused via 
the mini-pumps and therefore full tumourigenesis was not 
observed.
ER positive human breast cancer differs from ER negative 
disease in several biological and clinical parameters.
ER negative breast cancer is usually hormone independent 
and tends to behave in a clinically more aggressive manner 
than ER positive breast cancer. Receptor negative tumours 
tend to be less well differentiated, more aneuploid and 
have a higher proliferative rate (measured indirectly 
using methods such as thymidine labelling index and the 
fraction of cells in S-phase estimated using flow 
cytometry of ethidium bromide stained, disaggregated 
tumour (12,13)).
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Recent biochemical studies in vitro suggest that ER 
negative breast cancer cells have a high constitutive 
secretion of certain growth factors including TGF-ce and 
IGF-I (29). As the cancer cells have surface receptors to 
these peptide factors, autocrine growth loops could 
provide these cells with a proliferative advantage.
The main, purely paracrine growth factor studied thus far 
in breast cancer is PDGF, to which the breast cancer cells 
themselves are insensitive, but which has marked effects 
on the surrounding stroma. PDGF is a potent mitogen for 
vascular endothelial cells and fibroblasts and can elicit 
chemotactic responses in fibroblasts and smooth muscle 
cells (28-31). It is possible that PDGF secreted by 
breast cancer cells would have a primary role in 
maintaining the fibro-vascular stroma required for tumour 
growth via paracrine growth factor loops.
The work described thus far has originated from cell 
lines. There is some evidence to suggest that primary 
breast cancers express transcripts for TGF-a , IGF-II and 
epidermal growth factor receptor (EGF-r). Travers et al 
(32) isolated mRNA from samples of tissue in biopsy 
specimens from 52 malignant and 15 non-malignant tumours 
of the breast and 4 samples of normal breast.
30
Transcripts for both TGF-a and its receptor, EGF-r, were 
found more commonly in carcinomas that were ER negative 
(64% and 87% respectively) than in those that were ER 
positive (27% and 30% respectively). Insulin-like growth 
factor II mRNA was present in all 15 samples of non- 
malignant tissue but was found (in considerably lower 
amounts) in only 11 of 21 (52%) carcinomas. EGF-r was 
also found in all non-malignant breast tissues, compared 
with 19 of 45 (42%) carcinomas. PDGF mRNA transcripts 
coexisted in all normal and benign tissues and carcinomas.
Regardless of the mechanism of production, activation and 
delivery of growth factors, they all elicit biological 
events from the cell surface. The target cell must 
possess the specific cell surface receptor to effectively 
bind the growth factor. There is a substantial clinical 
data base for EGF-r, which binds both EGF and TGF - a  , in 
primary breast cancer specimens.
In a prospective series conducted by Sainsbury et al (33), 
135 patients with operable breast cancer underwent either 
lumpectomy with axillary sampling (25 patients) or simple 
mastectomy (110 patients). EGF-r concentration was 
measured by a radioligand binding assay in each tumour 
specimen. The authors found that there was a significant 
inverse relation between EGF-r and ER status and a 
significant association with tumour size and poor 
differentiation.
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The relapse-free survival and overall survival were 
significantly worse for patients with EGF-r positive 
tumours compared with EGF-r negative tumours.
Multivariate analysis of the parameters associated with 
prognosis showed that EGF-r status was the most important 
variable in predicting relapse-free and overall survival 
in lymph node negative patients and the second most 
important variable in lymph node positive patients. It 
would appear therefore that measurement of EGF-r 
concentration is of some clinical utility and might define 
a subgroup of node negative patients who would benefit 
from adjuvant chemotherapy.
It has become increasingly clear that there is a close 
relationship between growth factors, their receptors and 
oncogenes (Table 1.1). Oncogenes are mutated forms of 
proto-oncogenes, which are genes involved in cell growth 
and differentiation. Both types of genes have been 
cloned, studied in detail and the basis of their 
"activation" in some tumours has been determined. The 
role of individual oncogenes in multistage carcinogenesis 
is not completely understood and their stage-specific 
action, in terms of initiation and promotion in mammary 
carcinogenesis, is not clear. Nevertheless, there are 
clear links between steroid hormones, growth factors and 
oncogenes in determining the behaviour of established 
human breast cancer.
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The membrane receptor for TGF-ce (EGF-r) is coded for by a 
gene that has 2 related genes which have the properties of 
oncogenes. The erb-B gene is homologous to EGF-r gene 
except that its protein product lacks an extracellular 
domain (34) . The second, closely related component is the 
neu oncogene, detected initially in a chemically induced 
neuroblastoma (35) . The protein product of this oncogene 
has an extracellular domain, but it binds neither TGF-o: 
nor EGF.
In a series of 189 human primary breast cancers , 
evaluation of alterations in the HER-2/neu gene revealed 
that amplification occurred relatively frequently and was 
found to be a significant predictor of disease-free and 
overall survival. An initial survey involved tissue 
samples from 103 primary breast tumours. DNA was digested 
with EcoRI and subjected to Southern blot analysis with a 
22P labelled HER-2/neu probe which detects a 13kb 
hybridising band in human DNA. Nineteen tumours (18%) 
showed evidence of HER-2/neu amplification. When all 
tumours were categorised according to whether they 
contained one, 2-5, 5-20 or >20 copies, no association was 
seen between any of these groups and oestrogen or 
progesterone receptor status, tumour size, or age at 
diagnosis. However, a trend was noted for nodal status in 
that 11% of node-negative patients, 10% of those with 1-3 
involved nodes and 32% with >3 involved nodes had gene 
amplification.
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For >3 positive nodes, the increase in amplification was 
significant (P < 0.05) compared with 0-3 positive nodes 
(36). .
A second study was therefore conducted on 86 breast 
cancers from node-positive patients for whom a median 
follow-up of 46 months provided relapse and survival 
information. After mastectomy, 49% of these patients 
received adjuvant systemic therapy alone, 17% radiotherapy 
alone and 19% received both. At analysis, 35 patients had 
relapsed and 29 had died with median times of 62 and 69 
months, respectively. Amplification of the HER-2/neu gene 
was found in 40% of this series and correlated 
significantly not only with number of involved nodes (P =
0 .002), but also with oestrogen receptor status and tumour 
size. Univariate analysis revealed a highly significant 
correlation between degree of amplification and both time 
to relapse (P<0.001) and overall survival (P = 0.0011). 
Moreover, patients with >5 copies had significantly 
shorter disease free and overall survival times (P = 0.015 
and P = 0.06, respectively). In predicting these end 
points, amplification was found to be superior to all 
other prognostic factors except nodal status which it 
equalled. In multivariate analyses, amplification 
remained a strong independent prognostic factor providing 
additional information even when other factors were taken 
into account (36).
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In the whole series of 189 breast cancers, rearrangements 
of the HER-2/neu gene were rare (3 cases) . Moreover, 
rearrangements or amplification of the EGFr gene occurred 
in only one and four cases, respectively. The phenomenon 
of gene amplification is therefore not general for 
tyrosine kinase-specific receptors in breast cancer. The 
data indicate that HER-2/neu may play a role in the 
biological behaviour and/or pathogenesis of human breast 
cancer.
The avian erythroblastosis virus is an acutely 
transforming retrovirus containing two oncogenes, v-erbB 
and V-erbA. Previous work from Waterfield and 
collaborators (37,38) showed that V-erbB is probably a 
truncated form of the chicken EGF receptor gene, but the 
origin of v-erhA has remained a puzzle. Construction of 
viruses that only expressed v-erbA suggested that this 
gene is not capable of inducing neoplastic transformation 
on its own but co-operates with tyrosine kinase oncogenes, 
such as v-erbB or v-src, to produce transformed erythroid 
cells with a high capacity for self renewal and a low 
capacity to differentiate. Recent data on the cloning and 
structure of human glucocorticoid receptors suggested 
that the c-erbA gene might also encode a steroid hormone 
receptor. It appears that there are at least two families 
of c-erbA genes located on chromosomes 3 and 17 and that 
these genes encode proteins capable of binding thyroid 
hormones (T3 and T4) with high affinity (39).
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Thus, the c-erbA gene appears to encode receptors for 
thyroid hormones. Thyroid hormone receptors are expressed 
at low levels in many different tissue types and it is 
possible -that alterations to c-erbA could be involved in 
many different types of tumour. The evidence suggests 
that the v-erbA protein is a constitutively activated form 
of the receptor that does not bind hormone with high 
affinity. Activation appears to result from point 
mutations, some of which occur in a putative DNA-binding 
domain. The viral protein may therefore bind to DNA in 
the absence of the hormone ligand and thus activate or 
suppress gene expression (39).
The role of erf-A, erbB, and neu oncogenes in mammary 
carcinogens1*is unclear, but as mentioned, preliminary 
clinical studies have demonstrated their usefulness in 
assessing prognosis of primary breast cancer.
Activation of host cell oncogenes by insertion of proviral 
DNA is a common mechanism of tumourigenesis by 
retroviruses used sucessfully to identify proto-oncogenes 
by transposon tagging. Two proto-oncogenes, int-1 and 
int-2, have been implicated in control of development of 
murine mammary glands (40-42). Although the int proteins 
are unrelated to each other, they both have a structure 
characteristic of signal transmitting molecules.
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The int-1 gene is the mouse homologue of the Drosophila 
segment polarity gene wingless and int-2 encodes a member 
of the fibroblast growth factor family.
In transgenic mice, expression of int-l linked to a murine 
mammary tumour virus long terminal repeat as a 
transcriptional enhancer has dramatic effects on the 
growth of the mammary gland. Benign mammary hyperplasias 
develop in both male and female animals and mammary 
tumours appear after long periods of latency, in mice of 
both sexes. Nevertheless, the authors comment that 
although all mammary epithelial cells express high levels 
of int-l, the number of mammary tumours which develop is 
small, implying that there are other factors which 
contribute to what is presumably a multistage process 
(43).
A similar study with similar results has been performed 
with enhanced expression of c-myc in transgenic mice. 
Several strains of transgenic mice bearing the murine 
c-myc gene fused to the long terminal repeat of the mouse 
mammary tumour virus have been bred (44). A high level of 
expression of the myc transgene was observed only in the 
mammary gland with minor expression in the salivary gland 
and small intestine. Their results suggested that 
deregulated myc expression was necessary, but not 
sufficient in isolation, to ensure mammary tumour 
production.
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Compared with colon or lung carcinomas where mutant ras 
genes are present in 30% or more of tumours, in breast 
cancer, ras gene mutation and activation is of low 
incidence (10% or less). A recent survey has shown that 
about 30% of primary breast tumours contain c-myc 
amplification but this does not correlate with clinical 
behaviour or other indices of biological behaviour (45). 
Therefore, no clear picture has emerged for the biological 
role of these oncogenes. If, as seems likely, multiple 
genetic changes are required during carcinogenesis, it 
will be difficult to separate important changes from 
epiphenomena. The studies on murine mammary 
carcinogenesis show that oncogenes are important in the 
early stages of tumour induction and that no one model 
will provide a single, adequate answer. More work is 
required to elucidate the nature of the secondary or 
cooperating events during mammary carcinogenesis in these 
murine model systems and then apply these to the molecular 
events occuring in the clinical setting.
Another group of genes involved in carcinogenesis, termed 
onco-suppressor genes, shares the property that their 
expression suppresses the oncogenic phenotype of cancer 
cells (46) . The study of phenotypic reversion of 
transformed cells, cell fusion experiments with normal/ 
malignant cells and ultimately transfer of chromosomes or 
cloned DNA sequences, has given great insight into the 
function of onco-suppressor genes.
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Following early epidemiological studies, Knudson developed 
a 2 hit theory which proposed that the development of the 
malignancy required 2 mutational events (47) . He 
recognised that retinoblastoma had a hereditary 
predisposition and proposed that in bilateral 
reinoblastoma a mutant gene was passed in the germline 
such that all cells in the body contained a mutation. A 
second mutation in the other allele of the same gene in 
the embryonic retina would lead to tumour formation. For 
the unilateral or sporadic form of the disease which has 
no familial predisposition, he suggested that somatic 
mutations affecting both alleles occurred in the same 
retinoblast. The retinoblastoma gene, located on 
chromosome 13ql4 has been isolated and cloned.
Cytogenetic studies in breast cancer indicate that a 
number of chromosomal deletions have been described 
involving: llpl4; chromosome 13; chromosome 17p. Several
cancers seem to involve defects in the same chromosomal 
location as breast cancer (eg colorectal carcinoma, 
bladder carcinoma, osteosarcoma, small cell lung cancer 
and Wilm's tumour).
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The mechanism by which the protein products of onco­
suppressor genes suppress the malignant phenotype is not 
known, but some preliminary evidence suggests that the 
105 kDa product of the retinoblastoma gene interacts with 
the human adenovirus 5 1 EIA protein, which is synthesised 
early in viral infection and together with the protein EIB 
is required for transformation of cells. The regions of 
the EIA that are required for transformation are precisely 
those that interact with the retinoblastoma gene product 
(48) .
The situation in breast cancer is less clear but as 
mentioned, a significant number of relevant chromosomal 
deletions has been described. It is likely that there 
will be significant interactions between oncogenes and 
onco-suppressor genes implying that the malignant 
phenotype will be maintained by the interplay of a range 
of genetic factors.
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SECTION 1.3 REVIEW OF BIOLOGICAL FUNCTIONS OF TGF-B AND
/
THEIR RELEVANCE IN BREAST CANCER
TGF-p, a polypeptide consisting of 2 subunits each of 112 
amino acids, was first identified by its ability to cause 
phenotypic transformation of rat fibroblasts using a soft 
agar colony forming assay (49-51) and was cloned in 1985 
(52). It is now known to comprise a super gene family 
with 4 closely related members (TGF-J3, TGF-j32/ TGF-P3, and 
TGF-^4) identified by gene cloning and sequencing 
techniques, which have similar and overlapping biological 
functions (53). It is clear that there is a high degree 
of conservation of amino acid sequence of TGF-p on 
comparing TGF-J3's from different species which implies 
that it is a molecule which is likely to be important to 
the cell's economy in evolutionary terms. This is borne 
out by the range of regulatory activities which TGF-B has 
in a large number of diverse cell types, both normal and 
neoplastic.
A series of independent findings has revealed other 
factors which are structurally and functionally related to 
TGF-p. They include activins (54), inhibins (55) and the 
Mullerian inhibitory substances (56) in mammals, as well 
as the product of the decapentaplegic gene complex of 
Drosophila (57).
41
The homologies of these proteins with each other reside 
mainly in the C-terminal domains of their precursors which 
are generally cleaved to form active dimeric proteins.
The conservation of multiple cysteines involved in 
intrachain and interchain disulphide bond formation is 
marked and presumably underlies the structural importance 
of these moieties.
TGF-p is a dimer (molecular weght 25,000) which can be 
reduced to two subunits which are not individually 
biologically active. It is stable under acidic 
conditions, and this forms the basis for its purification 
from platelets (51). The gene has been cloned (52) and it 
is apparent that the monomer of 112 amino acids is derived 
by proteolytic cleavage from a precursor protein of 391 
amino acids, of which the monomer is cleaved from the C- 
terminal end of the protein. The precursor is rapidly 
cleaved to active monomer under acidic conditions, but the 
physiological mechanism whereby TGF-p is activated is 
unclear (58) . This is obviously an important potential 
site for the regulation of TGF-p's activity and more 
research is required in this area.
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TGF-p binds to specific, high affinity cell surface 
receptors, which are fairly ubiquitously expressed (58). 
Massague and coworkers (59) have used an affinity 
labelling method with radio-iodinated ligand to identify 
TGF-B receptors. They have shown that there are 3 cell 
surface glycoprotein receptors for TGF-p.
Two of the three cell-surface receptors displayed by many 
cells, glycoproteins of 55 kd and 85 kd have an affinity 
for TGF-B^ that is 10-fold higher than for TGF-p2/* the 
functions of these 2 receptors nevertheless remain 
unknown. The third receptor type is a 280 kd glycoprotein 
which does not discriminate between the various TGF-p 
molecules, but has been implicated in the mediation of a 
range of cellular effects of TGF-^3. The post receptor 
signal transduction pathways which are activated by 
binding of TGF-^ to its receptor have not been fully 
characterised but there is some evidence to suggest that 
it stimulates an increase in cellular inositol 
triphosphate levels which is maintained for several hours 
(59).
TGF-B has numerous effects on cell function which are 
relevant to mammary carcinogenesis. The original studies 
describing the discovery of TGF-p measured its ability to 
stimulate proliferation of NRK fibroblasts in soft agar.
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In a cell of mesenchymal origin, whether TGF-|3 stimulates 
or inhibits cell proliferation is a function of the entire 
set of growth factors which are operant within the 
microenvironment of the cell. For example, TGF-p 
stimulates the growth of c-myc transfected fibroblasts in 
the presence of PDGF (60), whereas similar concentrations 
of TGF-^5 inhibit fibroblast proliferation in the presence 
of EGF (61).
TGF-p stimulates mesechymal cells to synthesise and 
secrete components of intercellular matrix such as 
laminin, fibronectin and collagen (62).
TGF-B is one of the most potent inhibitors of epithelial 
cell proliferation yet discovered. Thus, it has been 
shown to inhibit the proliferation of normal mammary 
epithelium, breast carcinoma cell lines, bronchial 
epithelial cells, keratinocytes, colonic mucosal cells 
and other malignant epithelial cells in culture (reviewed 
in 63) .
Although TGF-p has a direct anti-proliferative effect on 
endothelial cells in vitro (64), it is an angiogenic 
substance in the intact animal due to its chemotactic 
effect on macrophages and other migratory cell types which 
themselves release strongly angiogenic substances (65) .
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From the point of view of tumour progression, TGF-p could 
be considered "anti-oncogenic" in that it has been shown 
that some malignant cells derived from TGF-p sensitive 
epithelial cells have lost their ability to be inhibited 
by the peptide (66). A related phenomenon has been 
reported for the A549 human lung alveolar carcinoma as it 
has been shown to secrete TGF-p in its precursor, latent 
form, suggesting that the cells have lost the ability to 
proteolytically activate the peptide (63).
Taking this information in concert, one could propose that 
the ideal tumour cell would synthesise and secrete TGF-B, 
which would help to support a fibro-vascular stroma 
required for tumour growth via paracrine effects on 
fibroblasts and angiogenic substance secreting cells, but 
not respond to the antiproliferative properties of TGF-p 
by either receptor deletion or loss of the TGF-p 
activating mechanism.
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FIGURE 1
Role of TGF-J3 in regulation of cell proliferation 
(autoinhibitory loop) and epithelial/ stromal cell 
interaction (paracrine lopps).
SECTION 1.4 THE BIOLOGICAL EFFECTS OF INTERFERONS IN
BREAST CANCER
There are 3 major classes of interferons - leukocyte or 
alpha interferon (Q'-IF) ; fibroblast or beta interferon; 
and immune or gamma interferon. New insights have been 
gained into their biochemistry, molecular biology and 
clinical mechanism of action because large quantities of 
purified interferons are available for study through the 
application of recombinant DNA technology.
The interferons have a huge range of biological effects 
(for review see 67) including antiviral properties and 
immmunological effects such as stimulation of the 
cytotoxic activities of lymphocytes, macrophages and 
natural killer cell activity. The interferons have also 
been shown to alter cell surface expression of 
class I and class II major histocompatability antigens and 
modulate cellular differentiation. These and other 
observations indicate that many of the effects of the 
interferons can be dissociated and are due to different 
molecular mechanisms.
The direct antiproliferative effect of interferon was 
first reported by Paucker (68). Despite preliminary 
studies on the distribution and affinity of interferon 
receptors, there are no general rules to predict which 
cells will be inhibited and which will not.
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In general, empirical results of antiproliferative and 
antitumour activity have been employed to use interferon 
as an antitumour agent although thee mechanism underlying 
the direct cytostatic effects of the interferons is 
unknown.
In breast cancer, a-IF has significant antiproliferative 
effects in a range of mainly ER positive cell lines (69). 
This prompted a series of phase II clinical studies using 
interferon as single agent in the treatment of advanced 
breast cancer. These initial trials recruited relatively 
small numbers of patients, but it did appear that QJ-IF did 
have useful clinical activity. However, more recent 
randomised prospective trials have failed to confirm its 
early promise and most experts feel that on balance, IF 
has only limited activity in advanced breast cancer and is 
less efficacious than conventional hormone and cytotoxic 
therapy (70).
Fibroblast interferon has been administered to patients 
with advanced breast cancer and induced a reduction in the 
size and number of skin metastases. The number of 
patients treated was small but it is interesting to note 
that the investigators biopsied skin metastases in 6 
patients and found that interferon increased expression of 
ER in these metastatic nodules (71).
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There is interest in the potential for a combination of 
cy—if and conventional horome treatment for breast cancer 
in an aduvant setting as there is some evidence to suggest 
that the interferons are more active in clinical 
situations with minimally low cancer burdens.
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SECTION 1.5 AIMS OF THESIS
The aims of this thesis are:
1. To determine the role of TGF-p in controlling
proliferation of human breast cancer cells in vitro.
2. To determine whether a-IF has a significant
cytostatic effect on human breast cancer cells in 
vitro.
3. To determine the mechanism of action ofce-IF' s 
induction of cytostasis.
4. To determine the effect of oncogene transfection 
(c-myc and H-ras) on epithelial response to 
exogenous growth factors.
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TABLE 1
GROWTH FACTORS AND THEIR RECEPTORS DEMONSTRATED 
ON HUMAN BREAST CANCER CELLS.
GROWTH FACTOR RECEPTOR
AGENT RELATED BREAST RELATED MODE OF
ONCOGENE CELLS ONCOGENE ACTION
PRODUCT PRODUCT
PDGF sis absent none paracrine
TGF-a none present neu/erb-B autocrine/
paracrine
TGF- none present none autocrine/
paracrine
IGF-I none present none autocrine/
paracrine
Oestradiol none present erb- A endocrine
50
CHAPTER II
MATERIALS AND METHODS
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SECTION 2.1.1 MATERIALS
All chemicals used were supplied by BDH Chemicals Ltd., 
Poole, Dorset unless otherwise stated.
REAGENT SUPPLIER
Acrylamide
Sigma Chemical Co.,
PO Box 14508,
St Louis, MO 63178, USA
Agar GIBCO Laboratories, 
Paisley, Scotland
Anti TGF - B Antibody R & D Systems Inc.,
614 McKinley Place, 
Minneapolis, MN 55413, USA
Bio-Gel P-60 column packing Pharmacia Ltd.
(Great Britain) '
Prince Regent Rd., Middlesex
Bio-Rad Protein Assay Kit Bio-Rad Laboratories,
27 Holmesdale Rd.,
Bromley, Kent
BSA Sigma Chemical Co.
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DMEM Medium (lOx)
Ecoscint
EGF
Foetal Calf Serum 
Geneticin
Glutamine (200mM)
Hank's Balanced 
Salts Medium
HEPES
a-interferon
Flow Laboratories, PO Box 17 
Second Avenue,
Irvine Industrial Estate, 
Ayrshire
National Diagnostics Ltd., 
Manville, New Jersey, USA
R & D Systems Inc.
Flow Laboratories
Schering Corporation, 
Kenilworth, NJ 07033, USA
Flow Laboratories
Flow Laboratories
Flow Laboratories 
Schering Corporation
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Isotopes: 3H - Thymidine 
32P - dCTP 
125i _ sodium iodide
Mercaptoethanol 
Nitrocellulose Membranes
Pepstatin
Phenylmethylsulphonyl- 
fluoride
Random Primed DNA 
Labeling Kit
Sephadex G-50
Tissue Culture Flasks etc
Trypsin
The Radiochemical Centre 
Amersham, Bucks.
Sigma Chemical Co.
Gene Screen Hybridisation, 
NEN Research Products, 
Boston, USA
Sigma Chemicals Co.
Sigma Chemicals Co.
Boehringer Mannheim Corp., 
Bell Lane, East Sussex
Pharmacia Ltd.
GIBCO Laboratories
Flow Laboratories
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SECTION 2.1.2 TISSUE CULTURE AND CELL LINES
The cells were all maintained in HEPES buffered Dulbecco's 
DMEM supplemented with 10% FCS (deionised distilled water, 
400ml; DMEM (10x), 45ml; 1M HEPES pH 7.3, 9 ml; sodium 
bicarbonate 7.5%, 2.5 ml; adjust to pH 7.4 with sodium 
hydroxide; glutamine (200mM), 5 ml; FCS, 50 ml). The 
cells were subcultured every week, when in use, whilst in 
the late exponential phase of growth, following a brief 
exposure to 0.25% trypsin. The cell lines used in this 
thesis are described below.
ZR-75 cell line: a human, ER positive breast carcinoma
cell line derived from the pleural 
effusion of a patient with metastic 
breast cancer obtained from the 
European Collection of Animal Cell 
Cultures, Porton Down, Salisbury, 
England.
MDA-41 cell line: a human ER negative breast carcinoma
cell line obtained from the European 
Collection of Animal Cell Cultures.
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NRK-49 F cell line:
CC1-64 cell line:
a normal rat kidney fibroblast cell 
line obtained from the European 
Collection of Animal Cell Cultures.
a mink lung epithelial cell line 
obtained from the European Collection 
of Animal Cell Cultures
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SECTION 2.2 PURIFICATION OF TGF-B
SECTION 2.2.1 PLATELET EXTRACTION
Rationale : This section deals with the methods developed
to purify TGF-B for subsequent experimental use.
Platelet concentrates (30-40 units, 2-5 days old) were 
obtained by courtesy of the Blood Transfusion Service (Law 
Hospital, Scotland) and centrifuged (3200 x g, 30 min.,
0°C) to remove remaining plasma proteins. The platelets 
were washed twice by resuspension in 500ml portions of 
Tris-HCl/citrate buffer and centrifuged as described. 
(Washing buffer: 9 vol of 17mM Tris-HCl,
pH 7.5/0.15M NaCl/0.1% glucose and 1 vol of acid/citrate/ 
dextrose buffer - this was prepared according to National 
Institutes of Health formula A: 8g citric acid
monohydrate/22g of dextrose (anhydrous)/26g of sodium 
citrate (dihydrate) made up to 1 litre with distilled 
water). Washed platelets (30-40g weight) were added to a 
solution of acidic ethanol (375ml of 95% (vol/vol) ethanol 
and 7.5ml of concentrated HC1, plus 33mg of phenylmethyl 
sulphonyl fluoride and 1.9mg of pepstatin as protease 
inhibitors) and immediately extracted in a Dounce 
homogeniser (4ml of ethanol/g of platelets).
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After incubation overnight at 4° C, precipitated proteins 
were removed by centrifugation (10,000 x g, 10 min, 0° C) 
and the resulting supernatant adjusted to pH 3 by addition 
of concentrated ammonia. Proteins and TGF-J3 activity were 
precipitated from the solution (overnight at 4° C) by 
addition of ethanol (2 vol, 0^ C) and ethyl ether (4 vol, 
0° C). The precipitate was collected by centrifugation 
and suspended in 1M acetic acid. TGF-J3 activity was 
solubilised by an overnight extraction at 4^C. 
Centrifugation clarified the solution; the supernatant was 
freeze dried or subjected directly to gel filtration. The 
amount of protein in the extract was determined by 
reaction with Coomassie blue (Bio-Rad Protein Assay) using 
bovine serum albumin as reference. In summary, 200ptl of 
Bio-Rad protein assay solution was aded to 775/U of 
distilled water and 25/tL of the test protein solution. 
Appropriate standards were prepared with BSA and standard 
curves were made plotting reference protein concentration 
against optical density at 595nm (Beckman-Dickinson 
Spectrophotometer, High Wycombe, Bucks). Protein 
concentrations in the unknown samples were derived by 
extrapolation from the standard curves.
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SECTION 2.2.2 PURIFICATION OF PLATELET DERIVED TGF-B:
The solubilised platelet extract (10ml in 1M acetic acid) 
was gel filtered at a flow rate of 20ml/hr on a column 
(4.4 x 115cm) of Bio-Gel P-60 equilibrated in 1M acetic 
acid. Fractions containing 5ml were collected. The 
elution position of TGF-p was determined by bioassay (as 
described below) and the fractions containing the peak of 
activity were pooled and freeze dried. The amount of 
protein in the pool was determined as above. The freeze 
dried residue was solubilised in 50mM acetic acid and 
injected onto a Mono-Q anion exchange column 
(4 x 40cm; Pharmacia Ltd), equilibrated in 50mM acetic 
acid with buffer flow rate of 60ml/hr. A linear gradient 
0-1M NaCl was introduced and 2ml fractions were collected. 
Individual fractions were assayed for TGF-p activity. 
Fractions (2ml) containing the peak of TGF-p activity werei
pooled and freeze dried. The residue was dissolved in 4mM 
HC1 and prepared for a final HPLC clean up. 1ml samples 
were run on a C-18 microbondapack column equilibrated in 
0.05% trifluoroacetic acid. The flow rate was 20ml/hr and 
a stepped gradient (15-40%) of acetonitrile was 
introduced. The 1ml samples corresponding to the peak of 
biological activity were freeze dried. Selected amounts 
of purified TGF-J3 were dried under vaccuum and analysed by 
SDS-polyacrylamide Gel (0.75mm, 12.5% acrylamide ) run at 
125V and stained with silver (Bio-Rad Diagnostics) under 
reducing (5% B-mercaptoethanol in the sample buffer) and 
non-reducing conditions.
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SECTION 2.3.1 BIOASSAYS FOR TGF-p:
SOFT AGAR COLONY FORMATION.
Rationale: This section describes the bioassays which
were developed for TGF-J3. They were used to determine 
eluted biological activity during TGF-B purification.
This bioassay for TGF-j3 determines the ability of the 
polypeptide to induce anchorage-independent growth of 
non-neoplastic NRK-49 fibroblasts by measuring the 
formation of colonies of cells in soft agar (72). Agar 
underlays (0.6% in 0.5ml of tissue culture medium) were 
poured in 35mm petri dishes and allowed to set.
EGF (2.5ng per dish) and sterilised samples which had been 
freeze dried following column chromatography were added in 
10[JL± of 4mM HC1. NRK-49 fibroblasts (5 x 10^) were added 
in 0.3% agar in culture medium to the petri dishes. The 
plates were then incubated at 37^C for 2 weeks in a 
humidified 5% C02 atmosphere without further feeding. The 
number of colonies was counted, unfixed and unstained at 
two weeks using phase contrast microscopy. Control plates 
with known quantities of commercially available TGF-p were 
also set up to determine a dose response curve.
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One unit of TGF-p activity is defined as that biological 
response resulting in 50% maximal colony formation (colony 
size ^ 3000 m2) in the presence of EGF (2.5ng/ml). The 
maximal response of the assay is about 2500-3000 
colonies/dish.
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SECTION 2.3.2 BIOASSAY FOR TGF-p: INHIBITION OF 
INCORPORATION OF —H-THYMIDINE
This bioassay for TGF-j3 depends on its ability of inhibit 
the incorporation of 3H-thymidine by mink lung epithelial 
cells in a dose dependent manner (73).
The mink lung epithelial cells (CCL-64 line) were seeded 
into 24 well plates at initial density of 5 x 104 cells 
and incubated at 37^ C in a 5% CO atmosphere. After 1 
hour the column samples to be tested were added and the 
cells incubated overnight for 22 hours. After 22 hours, 
0.5/iCi 3H-thymidine (80Ci/mmol) was added to each well and 
incubated at 37^ C for 2 hours. The cells were fixed in 
lml of methanol/acetic acid (3:1 vol/vol) per well, for 1 
hour at room temperature. The cells were then washed 
twice with 80% methanol and allowed to dry. 0.5ml of 
0.25% trypsin solution was added to every well. After 1 
hour, 0.5ml of 1% SDS was added and 5 minutes later the 
resulting mixture transferred to vials for liquid 
scintillation counting (Beckman Dickinson Scintillation 
Counter). Results were expressed as the % inhibition of
"3
incorporation of JH-thymidine relative to control 
(untreated) cultures. Known quantities of TGF-J3 were 
added to prepare a dose response curve.
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SECTION 2.4 THE EFFECT OF CX-IF AND TGF-j3 ON
PROLIFERATION OF BREAST CANCER CELLS
Rationale: Basic experiments were performed to determine
if ce-IF and TGF-B have direct antiproliferative effects on 
ER positive and ER negative breast cancer cell lines.
Human breast carcinoma cells (ZR-75 and MDA-41 cell lines) 
were seeded at initial density of 5 x 10^ cells/well in 24 
well tissue culture plates in standard tissue culture 
medium. They were incubated at 37^C in a 5% C02 
atmosphere. The cells were exposed to ce-IF (500iu/ml) or 
TGF-B (50pM) continuously, with a medium change (plus 
ce-IF and TGF-p) every 2 days. Cells were harvested by a 
brief exposure to 0.25% trypsin, every 2 days and cell 
number counted using an electronic cell counter (Coulter 
Electronics Ltd., Hialeah, FL33010, USA). Control, 
untreated cultures were set up also to determine the 
normal growth characteristics of each cell line.
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SECTION 2.5 ESTIMATION OF CELLULAR OESTROGEN 
RECEPTOR CONTENT
Rationale: There is some ambivalent experimental evidence
suggesting that a-IF can influence phenotypic expression 
of ER, both in vivo and in vitro. These experiments were 
undertaken to clarify this situation and to extend the 
observations on the mechanism of direct cytostasis induced 
by the interferons. As oestradiol is an important trophic 
hormone for ER positive breast cancer cells, reduction in 
expression of ER could lead to reduction in the cell's 
ability to respond to the mitogenic oestradiol.
Measurement of ER concentration was made in late 
exponential phase for ZR-75 cells. The cells were grown 
in standard culture medium in 25cm2 tissue culture flasks. 
The ZR-75 cells were exposed to ce-IF (500iu/ml) or 
TGF-p (50pM) for varying periods of time (up to 96 hours), 
washed with ice cold phosphate buffered saline and 
harvested by scraping with a rubber policeman prior to ER 
estimation. Six flasks were treated at each duration of 
exposure to cx-i f .
The ER assays were performed by Dr R E Leake, Department 
of Biochemistry, University of Glasgow and were based on 
standard Scatchard analysis of a 2H-oestrddiol competitive 
binding assay using 100-fold excess, unlabelled 
diethylstilboestrol to eliminate non-specific binding.
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The results were expressed as fmol ER protein per mg 
cellular DNA. The inter and intraassay coefficients of 
variation were less than 10%.
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SECTION 2.6 STUDIES WITH AN ANTI-TGF-B ANTIBODY
I
Rationale: These experiments were undertaken to test the
hypothesis that TGF-p secretion mediates the cytostatic 
effect of a-IF. If this hypothesis is correct, co­
incubation with a-IF and an antibody which will 
biologically neutralise TGF-p should reduce the 
antiproliferative effects of ce-lF.
A commercially available polyclonal antibody against TGF-p 
was tested for its ability to neutralise the biological 
effects of TGF-B in the mink lung epithelial bioassays 
(section 2.3.2). TGF-p (lng) was incubated with 
increasing concentrations of the antibody (l-50ju,g) for 2 
hours at room temperature prior to addition to the CC1-64 
cells with subsequent processing as previously described.
In subsequent experiments, ZR-75 cells were treated with 
anti-TGF-p antibody (50fig/ml) and a-IF (500iu/ml) for 4 
days and cell number determined at intervals as described 
in section 2.4.
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SECTION 2.7 ASSAY FOR TGF-p RECEPTORS
Rationale: These experiments were performed to estimate
the number and binding affinity of TGF-p receptors on the 
ZR-75 cell surface.
The chloraraine T method was used for iodination as the 
biological activity of the radioiodinated protein tends to 
be maintained with this procedure. 5 fig of TGF-p was 
placed in a siliconised Eppendorf tube. lOfil of 1. 5M 
potassium phosphate (pH 7.4) was added, followed by 
0.75mCi sodium iodide^2^. Then 3 x 5fil aliquots of 
chloramine T (O.lmg/ml), in 50mM sodium phosphate buffer 
(pH 7.4) was added, separated by 2 minutes to allow 
reaction to occur. Then 20fll of 50mM N-acetyl tyrosine 
was added, mixed and allowed to stand at room temperature 
for 2 minutes. This was followed by 200fil of 60mM 
potassium iodide and 200fil of 8M urea (ph 3.2). The 
reaction mixture was transferred to a Pharmacia disposable 
column (20 x 0.7cm) loaded with sephadex G-50 and 
equilibrated in column buffer (4mM HC1, 75mM NaCl, 0.1% 
BSA) . The 125I-TGF-p was eluted from the column and its 
biological and specific activity was determined (58).
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The general procedure for the determination of cellular 
receptors for TGF-p depends on a competitive radiological 
assay using the radio-iodinated polypeptide.
ZR-75 cells were seeded in standard culture medium at 1.5- 
1.8 x 105 cells per ml (with 1 ml per well) in a 24 well 
plate, 24 hours prior to the binding experiment.
A series of samples were prepared containing "cold" and 
"radioactive" TGF-p.
Unlabelled TGF-p : lOng of TGF-B stock solution in
binding buffer. (8 doubling dilutions of stock solution 
was made.)
Radioactive TGF-B: 125I-TGF— p stock was diluted to a
final concentration of lOOpM. 12^I-TGF-p (200/tL) was 
added to each of the 8 dilutions of unlabelled 
TGF-p (200jul) .
Twenty four hours after seeding, the cells were washed 
twice with 1 ml of binding buffer at room temperature.
200/fL. of mixture (i.e. ^2^I-TGF-p + diluted unlabelled 
TGF-p) was added to each well. Duplicate samples for each 
dilution of unlabelled TGF-p were performed. The cells 
were incubated with the TGF-p for 2 hours at room 
temperature and were then washed with 1ml of Hanks/BSA 
(500ml of Hanks salts plus 500mg BSA) at 0° C.
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Following this, the cells were solubilised by adding 750/U 
of prewarmed triton/glycerol/Hepes (2ml 1M Hepes; 
lml triton X 100; 10ml glycerol; 87ml water) to each well. 
They were placed in an incubator and held at 37°C for 30 
minutes. The solution (600/xl) was then removed from each 
well and transferred to vials for counting by liquid 
scintillation (Beckman Dickinson Scintillation Counter). 
Appropriate controls (addition of binding buffer only) 
were present on each plate.
The data were analysed by the method of Scatchard using an 
in house computer programme based on the Marquhardt 
algor ythm.
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SECTION 2.8.1 ISOLATION OF RNA AND NORTHERN BLOTTING
Rationale: a-IF has been shown to influence the rate of
transcription and mRNA stability for a range of genes.
This series of experiments was performed to determine the 
influence of (X-IF on rates of transcription and steady 
state mRNA pools for genes of interest (ER and TGF-p) in 
breast carcinoma cells. This should allow definition of 
the molecular site of action of a-IF.
At varying intervals following treatment with a-IF 
(500iu/ml), subconfluent cultures of ZR-75 cells 
(approximately 107) were washed twice with ice cold 
phosphate buffered saline, trypsinised and collected by 
centrifugation (2,000 rpm for 5 minutes, 0° C ) . RNA was 
prepared from the cell pellet. 10ml of phenol 
equilibrated with 0.3M sodium acetate were added to the 
cell pellet, followed by a solution comprising 0.3M sodium 
acetate; 0.5% SDS; 5mM EDTA. The mixture was shaken in a 
rotary stirrer for 5 minutes and 10ml of chloroform was 
added and shaken for a further 5 minutes. The cellular 
extract was centrifuged at 3,000 rpm for 5 minutes at 4° C 
and the upper aqueous phase retained. This was re­
extracted with 5ml of chloroform, shaken and centrifuged 
again. The aqueous phase was transferred and 2 volumes of 
ice cold ethanol were added and the resulting solution 
held at -20° C for 2-4 hours.
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This was then centrifuged at 3,000 rpm for 60 minutes and 
the resulting pellet resuspended in 5ml DEPC treated 
water. An equal volume of 4M lithium chloride was added 
and kept at 4®C overnight. The resulting solution was 
then centrifuged at 10,000 rpm at 4°C for 30 minutes. The 
RNA pellet was resuspended in 250/tL of 5mM magnesium 
chloride. DNA was degraded by the addition of DNA'se I 
(lfil of 20jttg/ml) for 20 minutes at room temperature. The
concentration of RNA in the sample was determined
spectrophotometrically at OD260nm*
The Northern blots were run according to Maniatis (73).
The gels were prepared by melting lg agarose in distilled 
water, cooled to 60° C and lOx concentrated gel running 
buffer (0.2M MOPS, pH 7; 50mM sodium acetate; ImM EDTA, 
pH8) and formaldehyde were added to give a respective 
final concentration in the gel of Ix and 2.2M. The RNA 
samples were prepared by adding 20/xg of RNA (in 4.5/tL of 
water) to 2fxl of lOx gel running buffer, 3.5/tL
formaldehyde and 10/tL formamide. This mixture was heated
at 55° C for 15 minutes. Two fil of sterile loading 
buffer (50% glycerol, ImM EDTA, 0.4% bromophenol blue,
0.4% xylene cyanol) were added and the samples layered on 
to the agarose gel.
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50ng of restriction fragments of DNA were used as 
molecular weight markers. The gel was run submerged in 
lx gel running buffer at 1 V/cm at 8c overnight. The 
buffer was constantly recirculated using a peristaltic 
pump. The gel was washed in water and the RNA transferred 
to the nitrocellulose filter. The filter was wet in 
water, soaked for 5 minutes in 20 x SSC (3M NaCl and 0.3M 
trisodium citrate) and then placed in contact with the 
gel. The blotting buffer was 20 x SSC and RNA transfer 
was complete in 15-24 hours. The blotting procedure was 
as described in Maniatis (73). When RNA transfer was 
complete, the blot was dried at room.temperature and baked 
in an oven at 80°C for 2 hours.
For the RNA dot hybridisation assay, a stock solution of 
RNA in water (500/ig/ml) was made. Eight doubling 
dilutions of 20/fL of stock RNA solution were made in 
water. The samples were heated to 65®C for 15 minutes, 
cooled on ice and condensation spun down in a 
microcentrifuge. Four /il samples were spotted onto a dry, 
nitrocellulose membrane (previously wet in water, soaked 
in 20 x SSC and air dried). After air drying, the 
membrane was baked at 80® C for 2 hours to immobilise the 
RNA.
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cDNA probes for TGF-p (1.3 Kb insert from Sp65-C17N, 
supplied by R Derynck), ER (1.6Kb insert from 0R3, 
supplied by P Chambon) and actin (Pst 1 insert cDNA of 
plasmid91, detecting alpha actin mRNA) were used. The 
DNA was labelled using a random primed DNA labelling kit 
(Boehringer Mannheim). The DNA sample was denatured by 
heating for 10 minutes at 95° C and subsequently cooled on 
ice. The following were added to an Eppendorf vial on ice: 
25 fig denatured cDNA 
3fx± dATP, dGTP, dTTP mixture
2fil hexanucleotide mixture in 10 x concentrated reaction 
buffer
5fil 50jU,Ci [ 22P] dCTP, 3000 Ci/mmol - made up to 19fxl 
with sterile redistilled water 
1/tL Klenow enzyme
The mixture was mixed and incubated for 30 minutes at 
3 7® C. The reaction was stopped by adding 2fil 0.2M EDTA 
(pH 8.0). The blots (Northern and dot blot) were sealed 
in polythene bags and prehybridised for 4 hours at 65® C 
in 10ml Church's buffer (0.5M Na2HP04 (pH7.2); 7% SDS;
ImM EDTA; 1% BSA). The denatured, radioactive cDNA probes 
were added to the blots and incubated overnight at 65® C.
The blots had a succesive series of washes; 3 x SSC and 
0.1%SDS, room temperature, 30 minutes; 1 x SSC and 0.1% 
SDS, 65® C, 1 hour.
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The dried membranes were autoradiographed on XAR-5 film 
(Kodak Ltd) at - 80^ C for 2 days. When required, the 
probes were eluted from the filters by washing in 0.1% SDS 
for 1 hour at 80^ C. They were then reprobed with the 
appropriate cDNA for human actin which acted as a "house 
keeping" probe to determine the equivalency of amounts of 
mRNA added to the gels.
The autoradiographs were scanned using a densitometer 
(Elmer Perkins Ltd) and expressed with respect to 
hybridisation to the actin probe.
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SECTION 2.8.2 NUCLEAR RUN ON ASSAY
Following treatment of ZR-75 cells in the late exponential 
phase of growth with GJ-IF (500iu/ml) for various periods 
of time (0, 0.5, 2, 12, 24 hours), the cells were washed 3 
times with ice cold phosphate buffered saline. The cells 
(107) were harvested by a brief exposure to 0.25% trypsin 
and pelleted by centrifugation (3000rpm, 15 mins, 4^ C). 
The cells were resuspended in lysis buffer (lOmM Tris-HCl 
(pH 7.4); lOmM NaCl; 3mM MgCl2; 0.5% (v/v) NP40) and held 
for 5 minutes on ice. The solution was spun at 500 x g 
for 5 minutes and the supernatant discarded. The nuclear 
pellet was washed by resuspension in 10ml of lysis buffer 
and spun again. The nuclear pellet was then resuspended 
in nuclear storage buffer (50mM Tris-HCl (pH 7.4); 5mM 
MgCl2; O.lmM EDTA; 40% (v/v) glycerol) in 100fil aliquots 
and stored at -80^ C until used.
For the nuclear run off assay, each reaction consisted of 
210/xl of nuclei, 60/tL of 5 x runoff buffer (5 x consists 
of 25mM Tris-HCl (pH 8.0); 12.5mM MgCl2 750mM KC1 and 
1.25mM triphosphates of adenosine, guanosine and 
cytosine). 32p_ labelled uridine triphosphate
(6/xl of 3000Ci/mM; 150/iCi) was then added and the mixture 
was incubated at 30^ C for 30 minutes, after which time 
15/tL of DNase I (5jLig/ml) in lOmM CaCl2 was added.
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After 5 minutes at 30® C the reaction was made 1 x SET 
(1% SDS; 5mM EDTA; lOmM Tris-HCl 7.4)) and proteinase K 
was added to give a final concentration of 200jLtg/ml.
After incubation at 37® C for 45 minutes, the solution was 
extracted with an equal volume of a mixture of phenol and 
chloroform and the interphase was again extracted with 
100 1 of 1 x SET. Ammonium acetate (10M) was added to the 
combined aqueous phases (original plus reextraction) to a 
final concentration of 2.3M and an equal volume of 
isopropyl alcohol was added and nucleic acid was 
precipitated (-70® C for 15 minutes). The precipitate was 
centrifuged in a microcentrifuge for 10 minutes and the 
pellet was resuspended in 100/fL of TE (10mm Tris-HCl, ImM 
EDTA) and centrifuged through a G-50 (medium) spin column. 
The eluate was made 0.2M in NaOH and after 10 minutes on 
ice, HEPES was added to give a final concentration of 
0.24M. Two and a half volumes of ethanol were then added 
and the solution containing the precipitate held overnight 
at -20® C. After centrifugation in a microcentrifuge for 
5 minutes, the pellet was resuspended in hybridisation 
buffer (lOmM TES, pH 7.4, 0.2% SDS , lOmM EDTA, 0.3M NaCl, 
1 x Denhardt's, and Escherichia coli RNA (250jug/ml) ) . 
Nitrocellulose filters containing plasmid DNA's were 
prepared with a Schleicher & Schuell Slot Blot Apparatus 
under conditions suggested by S and S, except that wells 
were washed with 10 x SSC. These filters were first 
hybridised in the hybridisation solution described above 
for a minimum of 2 hours at 65® C.
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After this preliminary hybridisation, the filters were 
hybridised to the runoff products in hybridisation 
solution for 36 hours. A typical reaction contained 2 ml 
of hybridisation solution with 1 x 107 cpm/ml. After 
hybridisation, the filters were washed twice for 15 
minutes in 0.1% SDS, 2 x SSC at room temperature and then 
washed at 60^ C (0.1% SDS, 0.1 x SSC) for 30 minutes. 
Filters were then exposed to Kodak XAR film in cassettes 
at -70^ for 2 days.
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SECTION 2.9 TRANSFECTION OF MINK LUNG EPITHELIAL CELLS
WITH ONCOGENE CONTAINING PLASMIDS.
Rationale: In view of the relationship between oncogene
products and growth factor-receptor-signal transduction 
pathways, it was considered relevant to determine the 
effect of oncogene transfection of epithelial cell 
response to exogenous growth factors. Attempts were made 
to introduce the relevant oncogenes into ZR-75 cells but 
it proved difficult to select stable transformants whereas 
it did prove possible to derive stable oncogene 
transfectants of the mink lung epithelial cell line, which 
had previously been well characterised in terms of growth 
factor responsiveness. The cellular response to mitogenic 
or antiproliferative stimuli will be governed not only by 
its genotypic milieu, but also by the other growth factors 
operant in the cell's microenvironment. Therefore, 
further experiments were performed to determine 
^H-thymidine incorporation by the transfected cell lines 
following exposure to combinations of EGF and TGF-B.
The transfections described in this section were performed 
by Dr Demetrios Spandidos.
Using the calcium phosphate precipitation technique (74), 
recombinant DNA plasmids (figure 2) were introduced into 
the mink lung epithelial line (CC1-64), described in 
section 2.1.
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The recombinant plasmids are shown in figure 2 and their 
construction has already been described (74-76).
Basically, the plasmids consisted of the aminoglycoside 
phosphotransferase (aph) gene (which confers resistance 
to geneticin and therefore allows selection of geneticin 
resistant colonies in vitro), the proto-oncogene or 
oncogene of interest, flanked by transcriptional enhancers 
such as the long terminal repeat from the Moloney murine 
sarcoma virus or the enhancer from the SV40 virus. 
Following transfection, geneticin resistant colonies were 
grown after plating of 2 x 105 cells in soft ag.ar 
(0.6% base coating , 0.3% cellular layer). Transfection 
efficiencies were expressed as the number of colonies 
grown per,jitg of plasmid DNA per 2 x 10^ cells. Each 
derivative line was expanded from a single clone and named 
according to the plasmid with which they were transfected; 
H06-N1 line transfected the normal Ha-ras 1 proto­
oncogene; H06-T1 line transfected with the human T24 
activated Ha-ras 1 gene; MLMC1 line, transfected with the 
human c-myc proto-oncogene.
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FIGURE 2
Schematic representations of recombinant 
plasmids used in transfection experiments.
The derivative cell lines were characterised in the 
following ways:
Southern blotting and hybridization. Restriction enzyme 
cleaved DNA was transferred to Genescreen (NEN Research 
Products) hybridization membrane by vacuum blotting using 
the Vacugene (LKB Pharmacia) vacuum blotting unit. 
Hybridizations were performed according to Maniatis et al 
(73), using random primed 32P-labelled probes at 42®C in 
50% formamide, 10% dextran sulphate, 0.1% SDS and 100jug/ml 
denatured salmon sperm DNA. Membranes were then washed at 
high stringency (0.1 x SSC, 0.1% SDS) at 65^C for 1 hour 
with three changes of wash solution.
Growth curves were performed by seeding 1000 cells/ml in 
1ml in the wells of 24 well plates, and counting by 
trypsinisation and electronic particle counting 
(Coulter Ltd) at daily intervals. The medium was changed 
at 3, 5, 7, 8 and 9 days.
Tumouriaenicitv was determined by injecting 1 x 10^ cells 
subcutaneously in the flank of nunu immune-deficient mice. 
Lag time to the appearance of the first detectable lump 
was measured and the growth rate was estimated by caliper 
measurements at regular intervals.
Histology was performed on haematoxylin and eosin stained 
10% formalin fixed 4 m sections.
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Response of transfected cell lines to exogenous growth
factors
The derivative cell lines were exposed to a range of 
concentrations of TGF-B (10-10,OOOpg) and 
EGF (10-10,OOOpg) in exactly the manner descibed in 
section 2.3.2. The results are expressed as the 
% JH-thymidine incorporation relative to untreated control 
cultures of the same cell line.
Additional experiments were performed with the parent 
CC1-64 cell line in which the cells were exposed to either 
a fixed concentration of EGF (lng) and increasing 
concentrations of TGF-B(l-8ng) or a fixed concentration of 
TGF-B (lng) and increasing concentrations of EGF (l-8ng). 
The cells were treated and processed as described in 
section 2.3.2.
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CHAPTER 3
RESULTS
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SECTION 3.1 PURIFICATION OF TRANSFORMING GROWTH FACTOR B
TGF-J3 was purified from the platelet extract by a three 
column procedure comprising gel filtration, ion exchange 
and HPLC. The crude acid-ethanolic extract of human 
platelets (about lOOmg of protein from 25g of washed 
platelets) induced NRK fibroblasts to form colonies in 
soft agar. Typical colonies are shown in figure 3 and the 
dose response curve to purified, commercially available 
TGF-J3 in fig 4. These are highly refractile, by darkground 
microscopy, and contain > 40 cells. The crude extract 
elicited 1 unit of TGF-p activity at a protein 
concentration of lOOng/ml. Throughout TGF-p purification, 
protein concentrations were measured by the Bio-Rad 
colourimetric protein assay. Standard curves are shown in 
figure 5.
Gel filtration of the acid-ethanolic extract on Bio-Gel 
P60 in 1M acetic acid resulted in the profile in figure 6 . 
The profile of eluted biological activity, assayed by NRK 
colony formation, is superimposed on figure 6 . The 
biological activity of TGF-p eluted with an approximate 
molecular weight of 15000. Pooled TGF-p fractions 
(50-125 from figure 6) amounting to approximately 5mg 
total protein from the initial lOOmg sample 
chromatographed, elicited 1 unit of biological activity at 
a protein concentration of 5-20ng/ml.
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The pooled fractions were freeze dried, reconstituted in 
50mM acetic acid and subjected to ion exchange 
chromatography on a Mono-Q column. The biologically 
active protein eluted in the void volume of the column 
(figure 7). The appropriate fractions were pooled and 
elicited 1 unit of activity at a protein concentration of 
lng/ml.
A final "cleaning up" procedure consisting of HPLC with a 
stepped gradient in trifluoroacetic acid/acetonitryl 
yielded a TGF-B preparation which elicited 1 unit of 
activity at a protein concentration of approximately 
0.lng/ml. The protein elution profile from the HPLC 
column is shown in figure 8 . The relative concentration 
in TGF-p activity at each stage of its purification, is 
summarised in Table 2. Approximately lOng of TGF-J3 was 
adjudged about 95% pure by silver staining of a SDS- 
polyacrylamide gel (figure 9).
The biological properties of purified, human platelet- 
derived TGF-p are summarised in Table 3. In the presence 
of EGF (2. 5ng/ml) , TGF-J3 elicits near maximal NRK colony 
forming activiity at 2ng/ml (figure 10). The biological 
activity of the growth factor was destroyed by reduction 
in mercaptoethanol; stimulation of NRK colony formation by 
an EGF/reduced TGF-p mixture was no greater than that of 
EGF alone.
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TGF-p assayed in the absence of EGF was no better than 10% 
FCS alone. The purified TGF-B produced an identical dose- 
response curve (figure 11) to commercially available TGF-p
*3
by inhibiting incorporation of JH-thymidine by mink lung 
epithelial cells (the dose which produced 50% inhibition 
of H-thymidine incorporation relative to control,
ID50 = 120pg/ml).
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FIGURE 3
Photomicrograph of typical normal rat kidney (NRK) 
fibroblast colonies in soft agar (magnification, x 10 ).
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FIGURE 4
Dose response curve: number of NRK fibroblast colonies 
formed in response to exogenous, commercially purified 
TGF-p (in presence of EGF, 2.5/\g/ml).
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FIGURE 5
Standard curves for Bio-Rad protein assay.
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FIG 6
Protein elution profile from Bio-Gel P60 column (------) .
The number of colonies formed by addition of 50/xg protein 
from each fraction is superimposed (----- ).
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Protein elution profile from Mono-Q column (---- -).
The number of NRK colonies formed by addition of 50fig of 
protein from each fraction is superimposed —  £) .
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FIGURE 8
Protein elution profile from HPLC column (----- ). The
number of NRK colonies formed by additon of 50fig of 
protein from each fraction is superimposed (------) .
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FIGURE 9
SDS-polyacrylamide gel electrophoresis of protein extracts 
at different stages.
Lane 1 Molecular weight markers
Lane 2 Pooled active fractions following
bio-gel chromatography
Lane 3 Purified transforming growth factor-
P (approximately 50ng)
ro w
o
>  o
(Q
in
X
— j.
O,I
13
m
30
o
or
O
Z
m
co
V
CO co
1  § o
3.
FIGURE 10
Dose response curve: number of NRK fibroblast colonies in
soft agar formed in response to purified TGF-p alone( o  ) 
or in the presence of epidermal growth factor (2 .5ng/ml)
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FIGURE 11
Dose response curve: % inhibition of ^H-thymidine
incorporation by CC1-64 cells in response to purified 
( • ) and commercially available ( A ) TGF-B.
SECTION 3.2 THE EFFECT OF CK-IF AND TGF-p ON THE 
PROLIFERATION OF BREAST CANCER CELLS
The ZR-75 cells grow exponentially with a doubling time of 
2 8 — 3 hours and MDA-41 cells with a doubling time of 
26— 4 hours.
ce-lF (500iu/ml) has a significant cytostatic effect on 
ZR-75 cells (figure 12a). After an initial lag phase of 
about 12-18 hours, there is an anti-proliferative effect 
which persists during exposure to ce-iF. When ce-IF is 
removed from the medium, the cells start to regrow at a 
rate roughly parallel to control, after a lag phase of 18- 
2 4 hours.
TGF-B has a more profound cytostatic effect at a 
concentration of 50pM, but with similar kinetics. On 
removal of TGF-p from the medium, the cells start to 
regrow after a lag phase of 24-36 hours (figure 12a) .
a-IF had no cytostatic effect on the ER negative MDA-41 
breast cancer cell line. However, TGF-J3 (50pM) had a 
similar static effect as demonstrated in the ER positive 
line (figure 12b).
Similar experiments were performed with a-IF at a 
concentration of lOiu/ml, but no cytostatic effect was 
observed on either cell line.
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FIGURE 12(a)
The influence of cy-interf eron (ce-IF) (500iu/ml) and 
TGF-p (50pM) on ZR-75 cell proliferation. The cells were 
exposed to each agent continuously for 6 days. Each point 
is the mean of 6 estimates and the vertical bar denotes 1 
standard deviation.
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FIGURE 12(b)
The influence of ce-interferon (ce-IF) (500iu/ml) and 
TGF-p (50pM) on MDA-14 cell proliferation. The cells were 
exposed to each agent continuously for 6 days. Each point 
is the mean of 6 estimates and the vertical bar denotes 1 
standard deviation.
SECTION 3 . 3 THE EFFECT OF OL-INTERFERON ON CELLULAR 
OESTROGEN RECEPTOR CONCENTRATION
The mean cellular ER concentration was 105 — 42 fmol/mg 
DNA.
Following treatment with a-IF, ER concentration fell to 
approximately 50% of control values by 24 hours and stayed 
at this reduced level for the duration of a-IF exposure 
(figure 13). When ce-IF was removed from the medium, there 
was a lag period of 24 hours before ER concentrations rose 
to control values.
TGF-p (50pM) also decreased ER expression, but to a lesser 
extent than a-lF. ER concentration decreased to about 60% 
of control values by 24 hours after exposure to TGF-J3, 
remained depressed but recovered to approximately control 
values (figure 14) when fresh medium without TGF-p was
I
exchanged.
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%  EXPRESSION OF OESTROGEN RECEPTOR 
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FIGURE 13
The influence of a-interferon (500iu/ml) on % oestrogen 
receptor (ER) protein concentration relative to control 
untreated cultures. The cells were exposed to a-lF for 
96 hours.
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FIGURE 14
The influence of TGF-p (50pM) on ER protein concentration 
relative to untreated controls. The ZR-75 cells were 
exposed to TGF-J3 for 96 hours. Each point is the mean of 
6 estimations and the vertical bar denotes 1 standard 
deviation.
SECTION 3.4 RADIO-IODINATION OF TGF-p AND CELL BINDING 
STUDIES
TGF-p was radio-iodinated as described to a specific 
activity of approximately 5fiC± per fig. The protein was 
95% pure, as adjudged by silver staining of SDS-acrylamide 
gels and maintained its biological activity (Table 3).
The whole cell binding data was analysed and plotted 
according to the Scatchard method using an in-house 
computer programme based on the Marquhardt algorythm 
(figure 15). There was an average of 5800 binding sites 
per cell with a binding dissociation constant (Kd) of 
70pM. The Kd is close to the concentration which was 
biologically active (section 3.2).
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FIGURE 15
Scatchard plot of whole cell binding data of I—TGF
ZR-75 cells.
SECTION 3.5 THE EFFECT OF Q?- INTERFERON ON TGF - p AND 
OESTROGEN RECEPTOR mRNA LEVELS
SECTION 3.5.1 TGF-p mRNA
Northern blot analysis revealed a single transcript for 
TGF-p at the expected size of 2.5 kb. Scanning 
densitometry of Northern blots (figure 16) revealed that 
there was significant induction of TGF-B mRNA steady state 
levels by 24 hours following treatment with ce-iF 
(figure 17) by about 8 fold relative to control, 
untreated cells. Similar quantitative results were found 
with dot-blots using the same RNA isolated during and 
after a-IF treatment (figure 18). TGF-B mRNA 
concentrations were maintained at elevated values until 
ce-lF was withdrawn from the medium on day 4 and then 
decreased rapidly to near control values 36 hours later.
It is interesting to note that the kinetics of induction 
of TGF-p mRNA are similar to the ce-IF effect on cellular 
proliferation. As cell division slows down, the 
concentration of TGF-p mRNA rises. The dual effects are 
maintained during exposure to Q?-IF and when fresh medium 
(without ce-IF) is added, the cells begin to regrow after a 
lag phase during which TGF-p mRNA levels decline.
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FIGURE 16
Northern blot of total cellular RNA probed with ^ P - c D N A  
for TGF-p following treatment of human breast cancer ZR-75 
cells with Of-IF for 72 hours.
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FIGURE 17
Fold increase (relative to control) in TGF-p mRNA in 
reponse to treatment with ce-IF between days 0 and 4. 
TGF-p mRNA was quantatively assessed by densitometric 
scanning of Northern blots hybridised with 22P-cDNA probe 
for TGF-p. Each point is the mean value of 4 distinct 
blots and the vertical bar denotes 1 standard deviation. 
The intra blot coefficient of variation for densitometric 
reading was always less than 5%.
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FIGURE 18
Dot blots of RNA from ZR-75 cells treated with CK-IF for 
72 hours was extracted and probed with 32-cDNA for TGF-p 
Eight, sucessive doubling dilutions of RNA were bound to 
the nitrocellulose filter in vertical columns. The size 
and intensity of the dot is related to the amount of 
specific RNA hybridised.
SECTION 3.5.2 ER mRNA LEVELS
Northern blots determined that the ER cDNA probe bound to 
a single mRNA species 6.3 kb in size, in agreement with 
published data (39) . Dot-blot analysis revealed that ER 
mRNA levels (figure 19) tended to parallel ER protein 
levels (figure 13), with an initial early decrease to 
about 50% — 4% of control, untreated cells, by 12 hours 
which was maintained at this reduced level during a-IF 
exposure. The maximum reduction in ER mRNA levels 
occurred before the maximal reduction in ER protein.
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FIGURE 19
20/xg of total RNA was extracted from ZR-75 cells at 
various stages during 24hour treatment with ce-IF and 
hybridised with JZ,P-cDNA for oestrogen receptor. The 
and intensity of the dot is related to the amount of 
specific RNA hybridised.
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SECTION 3.5.3 NUCLEAR RUN-ON ASSAY
The kinetics of mRNA induction were assessed using a 
nuclear run-on asay. Transcription of the TGF-p gene was 
induced following a delay of 24 hours and was maintained 
for the duration of exposure to ce-IF (72 hours), 
returning to control values within 36 hours following 
withdrawal of a-IF (figure 20) . The kinetics of the 
effect of a-IF on inducing transcription of the TGF-p gene 
are similar to those seen for steady state accumulation of 
TGF-p mRNA in section 3.5.1. B-actin transcription was 
used as control and was fairly constant throughout 
exposure to a-lF.
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FIGURE 20
A - Slot blots of TGF-p mRNA induction in response to 
treatment with ( X - I F  (500iu/ml) for 72 hours. B-actin 
cDNA was used for control purposes.
B - The graph shows the integrated densitometer tracings 
of the TGF-p autoradiograph in A.
SECTION 3 .6 THE EFECT OF ANTI-TGF-p ANTIBODY ON THE 
CYTOSTATIC RESPONSE TO CL- INTERFERON
*3
TGF-p inhibits incorporation of JH-thymidine by mink lung 
epithelial cells in a dose-dependent fashion (figure 11) 
with an ID5q of 120pg/ml. By incubating a fixed 
concentration of TGF-p (lng/ml) with varying 
concentrations of a commercially available anti-TGF-B 
polyclonal antibody, it was possible to demonstrate that 
the antibody could neutralise the effects of TGF-p in the 
bioassay in a dose dependent manner (figure 21). It is 
apparent from figure 21 that 50fig of antibody abolished 
the activity of TGF-p (Ing) in the mink lung assay.
In a series of subsequent experiments, ZR-75 cells were 
exposed to CX-IF (500iu/ml) and 50fig of anti-TGF-p antibody 
for 4 days. As can be seen from figure 22, a-IF has a 
significant cytostatic effect (similar to figure 12a), but 
this was abrogated by the addition of the anti-TGF-p 
antibody. When Oi-IF and the antibody were removed from 
the medium, the cells started to regrow after a short lag 
phase. The suppliers of the antibody have performed 
experiments which indicate that the antibody does not bind 
to qj-IF (personal communication, R & D, Minneapolis) .
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FIGURE 21
Dose response curve: the degree of neutralisation of the
effects of lng of TGF-p in the mink lung assay by 
increasing amounts of anti-TGF-p polyclonal antibody.
Each point is the mean of 4 estimations and the vertical 
bars denote 1 standard deviation.
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FIGURE 22
The effect of anti-TGF-p antibody on the cytostatic 
efficacy of C¥-IF (500iu/ml; 4 day exposure) on ZR-75 
cells. Cells were untreated ( • ), treated with
Oi-IF alone ( o ) or a-lF plus anti-TGF-p antibody a 
(50/ig/ml; 4 day exposure) . The antibody alone had no 
antiproliferative effects. Each point is the mean of 6 
estimations and the vertical bars denote 1 standard 
deviation.
SECTION 3.7.1 THE EFFECT OF ONCOGENE TRANSFECTION ON THE
SENSITIVITY OF EPITHELIAL CELLS TO TGF-p 
AND EGF
Two or three derivative cell lines transfected with 
c-myc (cell line = MLMC)# H-ras proto-oncogene 
(cell line = H06N1) and activated H-ras oncogene 
(cell line = H06T1) were expanded from single colonies.
Southern blot analysis of the c-myc transfected cell line 
(MLMC) hybridised with P-labelled human c-myc probe 
isolated by PVU II/Bgl II cleavage of PMC 41 and spanning 
exon 2. The 8Kb human specific Hind III/EcoRI fragment 
encompassing the entire human c-myc gene was observed in 
cell line MLMC and was absent from the parental line line 
CC1-64.
Southern blot analyses of H-ras transfected cell lines 
hybridised with 32P labelled H-rasl probe isolated by 
Sma I/SST I cleavage of PT24C3 and spanning exons 1-4.
The 6 .6Kb human specific Bam HI fragment encompassing the 
H-ras gene was observed in cell line H06T1. An H-ras 
specific fragment of higher molecular weight was observed 
in cell line H06T1 resulting from a probable integration 
of H-ras sequences with in the 6 .6Kb fragment with 
endogenous mink lung sequences. The parental line CC1-64 
shows no hybridisation to the human H-ras probe 
(Dr J C Lang, personal communication).
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Immunocytochemical staining of fixed cells with monoclonal 
antibodies directed against human c-myc and H-ras 
proteins showed that human ras protein was present in both 
the ras transfected lines and that human myc was 
detectable in the MLMC line (Z Khan, personal 
communication).
The growth characteristics and tumourigenicity of the 
derivative cell lines were evaluated by Dr M Z Khan, CRC 
Department of Medical Oncology.
Although the parental line is epithelioid, the activated 
H-ras-transfected line lost its epithelial morphology and 
showed a bipolar or fibroblastoid shape with evidence of 
piling up. Chromosomal analysis gave a diploid number of 
30 and there was no indication of a major ploidy change, 
or gross chromosomal abnormalities in the transfected cell 
lines.
All the lines grew rapidly with doubling times under of 20 
hours.and a short lag period of around 5 hours 
(table 4). The population doubling times decreased from
19.5 hours in the parental line to 14.1 hours in the 
mutant and normal H-ras-transfected lines with the c-myc- 
transfected line intermediate at 18.2 hours. The 
saturation densities increase from 5.7 x 105 cells/cm2 in 
the CC1-64 and MLMC cells to 1.1 and 1.2 x 10^ cells/cm2 
in the H06N1 and H06T1 cells respectively.
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When 1 x 10° cells of each line were implanted in the 
flanks of nunu mice, 20% formed tumour from the CC1-64 
cells, while 100% formed tumours in all the other groups 
(table 5). The lag period for the cell tumour was 60 days 
while that of the MLMC tumours was 43 days, the H06N1 35 
days, and the H06T1 7 days (Table 5). A similar 
relationship was seen in the doubling times of the tumours 
with the CC1-64 cell tumour growing the slowest, and the 
H06T1 the fastest.
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SECTION 3.7.2 THE EFFECT OF ONCOGENE TRANSFECTION ON
EPITHELIAL CELL RESPONSE TO EXOGENOUS 
GROWTH FACTORS. TGF-B AND EGF.
The cellular response of the derivative lines to TGF-p is 
summarised in figure 23. The CC1-64 and H06N1 lines 
respond in an identical fashion to TGF-B in a dose 
dependent manner. The activated H-ras transfected line 
does not respond, even at high TGF-B concentrations and 
the MLMC line has an intermediate response.
EGF stimulates incorporation of ^H-thymidine by CC1-64 and 
H06N1 cells to a similar extent whereas the c-myc 
transfected line has an exaggerated response and the H06T1 
cells do not respond to EGF (figure 24).
The effect of combined treatment with EGF and TGF-p on 
^H-thymidine incorporation by CC1-64 cells is summarised 
in figures 25a and 25b. TGF-B reduces the stimulatory 
effect of EGF whereas EGF reduces the inhibitory, effect of 
TGF-p.
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TABLE 2
THE EXTENT OF CHROMATOGRAPHIC PURIFICATION OF
TRANSFORMING GROWTH FACTOR-B ACTIVITY BY STAGEI _ ~~
TGF-B Preparation Protein Fold
Concentration Concentration
(eliciting 1 unit (relative to 
of activity) crude extract)
Crude extract lOOng/ml -
Biogel fractions 5ng/ral 20
Mono-Q fractions Ing/ml 100
HPLC fractions 0.Ing/ml 1000
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TABLE 3
BIOLOGICAL EFFECTS OF PURIFIED PLATELET-DERIVED TGF-p
Sample Number of Colonies
(10%)
TGF-p concentration = lng/ml 
EGF concentration = 2.5ng/ml
(^3 00 0/un )
TGF-B + EGF 1968 ± 185
Reduced TGF-p + EGF 268 - 48
EGF alone 372 - 56
TGF-B alone
I
88 ± 32
Foetal Calf Serum 50 - 18
125I-TGF-p + EGF 1705 - 362
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TABLE 4
SUMMARY TABLE OF DOUBLING TIME AND SATURATION 
DENSITY FOR PARENT AND TRANSFECTED CELL LINES
All experiments performed in 10% FCS, 
F10:DMEM, and glutamine (lOmM).
(Mean ± standard deviation, n=6)
Cell Line Transfection Population
Doubling Time 
(PDT) (hours)
Saturation 
Density(SD) 
Cells/cm2
CC1-64 none 19.5 - 0.5 5.7 x 10'
MLMC myc 18.2 - 0.4 5.7 x 10'
H06N1
H06T1
+H-ras 14.1 - 0.9
Proto-oncogene
H-ras-1
Activated
14.2 ± 0.5
1.1 x 10'
1.2 x 10'
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TABLE 5
Sublines
CC1-64
MLMC
H06N1
H06T1
GROWTH CHARACTERISTICS OF PARENT AND 
TRANSFECTED CELL LINES ON IMPLANTATION 
INTO nu nu MICE
(Mean — 1 sta:
Latent Period 
(vol>33mm3) 
(Days)(4x4mm)
60.0 ± 5.2 
n = 3
43.4 ± 3.9 
n = 9
35.0 - 1.3 
n = 9
7.1 ± 0.8 
n = 9
deviation) 
Take(%)
21.4 
n = 14
100
n = 12 
100
n = 12 
100
n = 12
Doubling 
Time (Days)
(400-800mm3)
9.0 ± 0.8 
n = 4
6.4 - 0.6 
n = 9
7.2 ± 1.0 
n = 9
4.5 - 0.2 
n = 9
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FIGURE 2 3
Dose response curve: the effect of TGF-p on ^H-thymidine
incorporation by parent and transfected cell lines. Each 
point is the mean of 6 estimations and the vertical line 
denotes 1 standard deviation.
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FIGURE 24
Dose response curve: the effect of EGF on ^H-thymidine
incorporation by parent and transfected cell lines. Each 
point represents the mean of 6 estimations and the 
vertical line denotes 1 standard deviation.
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FIGURE 25
The effect of a fixed concentration of EGF (lng) on 
the dose-response curve to TGF-J3 in the mink lung 
epithelial assay. Each point represents the mean of 
estimations and the vertical line denotes 1 standard 
deviation. ( • ) EGF + TGF-p, ( o ) TGF-B alone
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FIGURE 25
The effect of a fixed concentration of TGF-p (lng) on 
the dose-response curve to EGF in the mink lung 
epithelial assay. Each point represents the mean of 6 
estimations and the vertical line denotes 1 standard 
deviation. ( o ) EGF + TGF-p, ( # ) EGF alone.
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DISCUSSION
Data are presented in this thesis which demonstrate the 
importance of growth factors in determining proliferation 
of breast cancer cells and how growth factor activity can 
be modulated by exogenous factors such as a-IF and by the 
genotypic milieu following oncogene transfection.
The initial phase of this thesis described purification to 
homogeneity of TGF-p (95% on silver staining of 
SDS-polyacrylamide gels) from expired platelets. The 
chromatographic method devised was based on the published 
method of Assoian et al (51) and made use of the acid 
stability of TGF-p.
The innovation introduced was the use of anion exchange 
mono Q columns following initial gel filtration 
chromatography and subsequent HPLC clean up using stepped 
acetonitrile gradients. The relative yield of TGF-p and 
its biological activity was very similar to that- reported 
by Assoian (51) but the run-time on anion exchange 
chromatography is significantly shorter than gel 
filtration in high concentration urea.
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The first series of experiments compared the 
antiproliferative effects of purified TGF-p with ce-IF. 
a-IF, at a concentration which is pharmacologically 
achievable in plasma with conventional clinical dosage 
regimens. a-IF induced cytostasis in ZR-75 cells which 
persisted for the duration of exposure. The cells started 
to regrow at a rate roughly parallel to control following 
removal of a-IF from the medium, after a lag phase of 
about 24 hours. Interestingly, a-IF did not have an 
antiproliferative effect on the ER negative cell line, 
MDA-41. TGF-p at a concentration of 50pM has a more 
profound antiproliferative effect on ZR-75 cells than 
a-IF, but with a similar kinetic profile (figure 12a). 
Growth of MDA-41 cells is inhibited by TGF-p, in a similar 
manner to the ZR-75 cells (figure 12b).
TGF-p has been shown previously to be a negative regulator 
of proliferation of both ER positive (79) and ER negative 
(80) cell lines. However, there is an obvious disparity 
between the response of the different cell lines- to ce-IF.
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The potential reasons for the lack of response of the ER 
negative cell line to ol-IF include:
a) insufficient interferon receptors
b) absence of ER
c) uncoupling of the mechanism by which ce-iF increases 
the rate of transcription of the TGF-p gene. The 
MDA-41 cells respond to TGF-p and therefore by 
imputation, they have sufficient receptors coupled to 
post receptor signal transduction pathways to react 
with any TGF-p released by the effect of ce-IF.
Subsequent experiments were performed with the ER positive 
ZR-75 cell line in order to determine if there was a link 
between the antiproliferative effects of a-IF and TGF-p.
In subsequent experiments it was shown that,ce-iF has a 
significant inductive effect on steady state mRNA levels 
for TGF-p, with an increase to some 8 fold relative to 
control cultures.
Again, the kinetics of response is such that there is a 
lag phase, an elevated plateau phase, followed by a 
decline to roughly control values. The period during 
which a-iF exerted its maximal,sustained antiproliferative 
effect corresponded with elevated TGF-p mRNA levels, the 
TGF-p mRNA levels declined within 24 hours of ce-iF 
withdrawal, at which time the cells began to regrow.
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Nuclear run-on assays showed that the site of action of 
ce-IF was to increase the rate of transcription of the 
TGF-p gene. The increase in the rate of transcription of 
TGF-p mRNA occurs faidly rapidly after treatment with 
a-IF, is maintained at a higher rate for the duration of 
exposure to Ce-IF and declines to normal on withdrawal of 
Q5-IF from the medium. The kinetics of this effect and the 
extent of induction of mRNA transcription parallel the 
rise in steady state TGF-B mRNA concentration. It is 
likely therefore that O'—IF exerts its modulating effect at 
a transcriptional level.
An essential component of any autocrine or paracrine 
growth control loop is the cell surface receptor for the 
polypeptide. It was possible to radio-iodinate TGF-p to a
i
high specific activity, yet retain biological activity for 
receptor binding studies.
Scatchard analysis of this data revealed that ZR-75 cells 
have 5800 high affinity binding sites (Kd = 70pM) 
per cell. These results are similar to those described 
for other TGF-p responsive cell lines such as NRK cells 
(58) and ER negative breast cancer cell lines (80). The 
binding dissociation constant of 70pM is similar to the 
concentration of TGF-p (50pM) which has been shown to have 
a significant growth inhibiting effect on ZR-75 and MDA-41 
cells.
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In developing the hypothesis that the cytostatic effects 
of ce-IF could be mediated by TGF-p, it seemed important to 
link Ctf-iF treatment to activation and secretion of TGF-p 
protein, as the mRNA data offer indirect support for the 
hypothesis.
Radioreceptor competition assays have been used (58) to 
measure TGF-p concentration in conditioned medium. An 
attempt was made to set up a similar assay in our 
laboratory but this did not prove sufficiently sensitive. 
There was unacceptably wide inter and intra-assay 
variation in the standard curves (>25%). In order to 
determine whether ce-lF increased the synthesis and 
secretion of active TGF-p into the cell culture medium, we 
coincubated the cells with both ce-iF and commercially 
available anti-TGF-p polyclonal antibody. In separate 
experiments it was proven that the antibody was bio­
logically neutralising in the mink lung epithelial assay. 
Coincubation of o:-IF with the antibody (the quantity of 
antibody capable of abolishing the effect of Ing. purified 
TGF-p in the mink lung epithelial assay) reduced the 
cytostatic effects of ce-iF by approximately 60%. Further 
increase in the concentration of antibody did not cause 
any further reduction in ce-IF's antiproliferative effect.
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Relatively little is known about the synthesis, packaging, 
secretion and binding of TGF-p to its cellular receptors, 
however the fact that the TGF-p antibody reduces the 
cytostatic effect of ce-IF by only 60% has 3 possible 
explanations:
a) The amount of antibody present is not adequate to bind 
to and neutralise the quantity of TGF-p produced by the 
breast cancer cells. We extended the dose response curve 
by increasing the concentration of antibody present in the 
culture medium but found no additional inhibitory effect. 
50/xg of antibody was enough to inhibit Ing of exogenous 
TGF-p in the mink lung epithelial assay, therefore it 
would seem likely that sufficient, even excess antibody, 
was added to neutralise TGF-p when coincubated with ce-iF.
b) TGF-p may be synthesised, secreted and activated by the 
cells but binds rapidly to its own receptors, therefore 
reducing the chance of interaction with the anti-TGF-B 
antibody in the culture medium. Examples of rapid, 
sequestered binding of ligand to receptor have been 
reported for other polypeptide growth factors (77, 78) .
c) Given the diverse effects that ce-lF has on cellular 
biochemistry, it is possible that other mechanisms 
contribute to the cytostatic effect of ce-IF.
107
As previously mentioned, ER play a central role in 
mediating the trophic effects of oestrogen on ER positive 
cell lines, such as ZR-75. It has been demonstrated that 
ce-IF (500iu/ml) reduces phenotypic expression of ER 
protein with a decrease in ER concentration to 
approximately 50% of control values by 24 hours of 
treatment. ER concentration is maintained at this 
depressed level for the duration of exposure to ce-lF and 
then rises to approximately normal values within 24 hours 
of withdrawal of ce-IF. The ER mRNA concentrations 
paralleled the response of ER protein to a-IF, although 
the fall in ER mRNA occurred 12 hours before the decrease 
in ER protein. It is interesting to note that TGF-p 
(50pM) reduced ER expression to 60% of control values and 
it is possible that TGF-B released in response to a-IF 
treatment could contribute to the reduction in ER induced 
by ce-IF.
These results are at variance with those of Van den Berg 
et al (81) who found that exposure of ZR-75 cells to 
continuous low levels of ce-IF (lOiu/ml) increased 
phenotypic expression of ER. The extent of the increase 
in ER levels ranged from 1.2 to 7.2 fold. This effect was 
inversely proportional to dose over the range 
10-1000iu/ml.
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In a small clinical study (71), sequential biopsy of 
accessible breast cancer metastases during therapy with 
Of-IF and measurement of tissue ER concentration, indicated 
that ER levels tended to rise following G'-IF treatment.
The possible differences for the discrepancy between the 
work reported here and that of Van den Berg include:
1. Different doses of ce-IF were used. The sorts of 
plasma concentrations of G-if that are found with clinical 
dose schedules for gj-if are in the range of 500iu/ml (69), 
which is why this concentration was chosen for the present 
study. It is known that the interferons have bell shaped 
dose response curves in vitro for a range of their 
immunological effects (80) and it is possible that this 
could extend to their anti-proliferative properties.
2. The cells were treated with ce-IF at different phases 
of growth . Van den Berg et al (81) noted a marked effect 
of cell density and in their hands, only cells seeded at 
low density exhibited induction of ER in response to (X-IF. 
The ZR-75 cells were treated at a relatively high density 
in the present report to facilitate the extraction of 
adequate quantities of RNA. Also it was considered closer 
to the cell kinetic situation found in vivo in the 
majority of breast carcinomas.
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3. There is considerable interlaboratory, phenotypic 
variation in human ER positive breast carcinoma cell lines 
and although derived initially from a common source, they 
have been available for so long and used so widely 
throughout the world that variation in a range of their 
biochemical properties has arisen (83).
Taken in concert, the results shown in this thesis imply 
that a significant proportion of the direct cytostatic 
effects of Cfr-IF are mediated by TGF-p in this human ER 
positive breast cancer cell line.
As previously mentioned, the interferons effect a range of 
immunological indices. However, the mechanisms underlying 
its direct, anti-proliferative action in vitro are 
unknown. The anti-proliferative activity of interferon 
was first reported by Paucker et al (68). There are no 
general rules to predict which cells will be inhibited and 
which will not, although interferon elicits its action by 
binding to cell surface receptors. Interferon treatment 
of murine and human cells results in the induction of 
several proteins in addition to those thought to be 
concerned with its antiviral activity 
(the 2,5-An-dependent endoribonuclease and Pl/eIF-2 
protein kinase-phosphoprotein phophatase system). A rise 
in the cellular concentration of a number of proteins 
ranging in apparent molecular weight from about 15,000 to
120,000 has been reported for a variety of different cell 
types in response to interferon treatment (82-85) .
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In certain instances the cDNAs corresponding to the 
interferon inducible mRNAs have been isolated, a number of 
which have been identified and shown to encode the 
following proteins: 2,5-An synthetase (88); 
metallothionein-II (89); thymosin B4 (89); major 
histocompatibility antigens (90); protein Mx (91); and 2 
proteins of unknown identity, one of 56Kd, (92) and the
other of 15Kd (93).
The kinetics of response of the inducible mRNA species is 
rapid and can be detected within 5 minutes to 2 hours 
after interferon treatment (89) . The mechanism underlying 
the rise in steady state mRNA levels can be due to 
increased rates of transcription of genes that are not 
normally transcribed or are transcribed at very low rates 
in the absence of interferon (94). It could also be 
related to post transcriptional mechanisms which alter 
mRNA stability (94). In terms of its antiproliferative 
effect, a-IF has been shown to decrease expression of 
certain oncogenes, which could be important in maintenance 
of the transformed phenotype. For example, treatment of 
Daudi cells with a-IF causes a significant decrease in the 
level of c-myc mRNA (95). Interferon treatment has also 
been shown to reduce the amount of H-ras mRNA and protein 
in mouse and human cells (96) and c - jCos mRNA in 
Balb/c 3T3 cells (97).
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If oncogene transcription/translation is important in 
maintenance of the transformed phenotype then the above 
biochemical effects could contribute to the anti­
proliferative action of os-IF. However, there are no 
significant correlations between the ability of a-lF to 
alter oncogene mRNA levels and induce cytostasis. The 
situation is complex as interferon expression can be 
induced by certain growth factors in an inhibitory 
autocrine loop; for example, platelet derived growth 
factor stimulates the rapid expression of a cell division 
competence gene family including c-myc and c-fos and the 
slower induction of expression of interferon-p. It is
i
possible that interferon-p may function as a feedback 
inhibitor of growth as the expression of the genes 
regulated by PDGF, including c-myc and c-fos, are 
inhibited by interferon treatment (97).
As yet, relatively little is known of the regulatory 
sequences to which interferon interacts with, in a trans 
sense, in terms of its ability to regulate gene 
expression. A consensus sequence has been derived from 
homologous sequences identified 5' to the putative 
transcriptional start sites of interferon inducible genes 
such as HLA and metallothionein but it is not clear how 
widely applicable this sequence is to other interferon 
inducible genes (98).
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Clearly this area would be of interest as it might be 
possible to identify consensus sequences flanking the ER 
or TGF-p genes through which a-IF acts to regulate gene 
expression. As is always the case, it is possible that 
the effects of a-IF on ER and TGF-B gene expression is 
indirect and depends on its induction of an intermediary 
protein. As mentioned, a-IF can have very rapid effects 
on gene expression (within 5 minutes) and it is possible 
that early induction of protein could lead to a secondary 
cascade effect on expression of other genes mediated by 
the early induced protein, rather than a-IF itself.
Lippman's group (79) have shown that the cytostatic 
effects of tamoxifen on an ER positive human breast cancer 
cell line (MCF-7) were mediated by an increase in 
synthesis and release of active TGF-p. These authors 
concluded that in MCF-7 cells, TGF-p is a hormonally 
regulated growth inhibitor with possible autocrine and 
paracrine functions in breast cancer cells. It has been 
shown in this thesis that ce-lF has a dual effect- on ER 
positive breast carcinoma cells that could lead to a 
synergistic antiproliferative interaction with tamoxifen.
113
a) Tamoxifen is an ER antagonist and therefore seeks to 
abrogate the ability of oestrogenic hormones to act as 
trophic factors by competitively blocking their 
interaction with ER. It has been shown in this study that 
a-IF decreases phenotypic expression of the ER which would 
seem a different means of accomplishing the same end-point
i.e. depletion of available ER for interaction with 
oestrogen.
b) Evidence has been provided here that at least some of 
the cytostatic effect of a-IF is mediated by TGF-B in the 
ZR-75 cell line. There is induction of TGF-p mRNA by ce-IF 
which was not described in tamoxifen treated cells by 
Krabbe et al (79).
If the end result is to increase active TGF-p available 
for auto-inhibition of cell division, then the fact that 
ce-IF (mRNA effect) and tamoxifen (increased synthesis and 
activation of TGF-p) accomplish this by different means 
again implies the potential for a synergistic interaction. 
There is some evidence to suggest that tamoxifen and a-IF 
could be usefully combined as Van den Berg et al (81) 
showed that there was a synergistic antiproliferative 
interaction between tamoxifen and ce-IF in vitro.
The combination of ce-iF and tamoxifen could be taken into 
animal models to see if the synergistic interaction is 
also found in vivo.
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Of course, if there were positive results, this would 
provide compelling evidence to initiate a prospective, 
randomised clinical trial (possibly in the adjuvant 
setting) comparing tamoxifen versus tamoxifen plus a-IF in 
patients with ER positive breast cancer.
In collaboration with Dr A Thompson, MRC Population 
Genetics Unit, Western General Hospital, Edinburgh, I have 
performed a series of experiments determining TGF-B mRNA 
expression in oestrogen and tamoxifen treated nude mice 
bearing ER positive (MCF-7 human breast carcinoma cell 
line) human breast carcinoma xenografts. Other than for 
discussions planning the experiments, my specific 
contribution was prepare Northern blots from RNA prepared 
from tumour tissue probed with ^P-cDNA for TGF-B and 
TGF-a:, as previously described. Dr Thompson established 
xenograft tumours from the oestrogen-dependent MCF-7 
breast cancer cell line in thymectomised, irradiated 
female CBA strain mice. Following infusion of oestrogen 
via osmotic mini pumps, there was an increase in. tumoural 
DNA synthesis and mitosis was stimulated with a consequent 
increase in tumour growth.
Laser densitometry was used to quantify mRNA on Northern 
blots and showed that with oestrogen stimulation, c-myc 
gene expression was increased whereas TGF-p expression was 
suppressed.
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However during the phase of oestrogen withdrawal, the 
tumours regressed and there was induction of TGF-p RNA. 
This xenograft system demonstrates changes in gene 
transcription in response to oestrogen. It thus provides 
an in vivo model for molecular and biochemical studies of 
hormone-sensitive human breast cancer (99).
In a further collaborative study with Dr Thompson, the 
expression of TGF-p mRNA has been quantified in mRNA 
extracted from breast tumour tissue from 45 untreated and 
11 tamoxifen treated patients using densitometry of 
Northern blots. In the 56 tumours, TGF-p mRNA expression 
was significantly higher in premenopausal women (p=0.05) 
but was independent of oestrogen receptor status and other 
clinical and pathological parameters.
Within tamoxifen treated patients, high expression was 
demonstrated in all 6 patients with progressive tumour 
growth whereas low levels were present in 4 of 5 with 
static tumour. These data suggest that failure of 
tamoxifen treatment in breast tumours is associated with 
high, rather than low, levels of TGF-p contrary to 
expectations from in vitro studies. If the asssumption is 
made that TGF-p is relevant to the mechanism of action of 
tamoxifen, then tamoxifen resistant tumours could arise 
due to a breakdown in the potential autoinhibitory loops 
described in figure 25.
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The fact that there are relatively elevated levels of 
TGF-p mRNA in tamoxifen resistant tumours could imply that 
the resistance to TGF-p occurs at a post-transcriptional 
level eg deletion of TGF-p receptors or loss of the 
ability to cleave the TGF-p precursor.
Although a potential autocrine inhibitory loop involving 
TGF-p has been described following treatment of ZR-75 
cells with G5-IF, one would expect that the final outcome 
of this treatment would depend on other factors which 
could interact with and alter the cellular response to 
TGF-p. For this reason, a series of experiments were 
performed to measure the response to exogenous growth 
factors of mink lung epithelial cells and their oncogene 
transfectants.
It was shown in this study that transfection of mink lung 
epithelial cells with c-myc and activated H-ras oncogenes 
altered the cellular reponse to exogenous growth factors. 
TGF-p inhibits incorporation of ^H-thymidine by mink lung 
epithelial cells in a dose dependent manner with an ID5q 
of 120pg/ml. EGF has the opposite effect with stimulation 
of ^H-thymidine incorporation. In addition, we have 
demonstrated that thymidine incorporation depends on the 
relative concentrations of the growth factors when the 
cells are exposed to them simultaneously.
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TGF-p and EGF antagonise each other in the mink lung 
assay. Presumably this reflects the situation in vivo in 
which stimulatory and inhibitory factors operate 
simultaneously in the microenvironment of the cells to 
increase the fidelity of control of proliferation.
The nature of the interaction between EGF and TGF-p is 
unknown. Assoian et al (100) noted a transient decrease, 
followed by an increase, in EGF receptors on NRK cells 
treated with TGF-p. Massague (101) has also investigated 
the interaction between exogenous growth factors and cell 
surface receptor number/affinity and has shown that TGF-p 
treatment decreases phenotypic expression of EGF receptors 
in exponentially growing NRK cells, but does not alter EGF 
binding by non-transformed mink lung cells. Coffey et al 
(102) demonstrated that TGF-p reversibly inhibited the 
growth of mouse keratinocytes by competitively 
antagonising the effect of EGF or TGF-ce. These authors 
concluded that the inhibitory effects of TGF-p were 
mediated by events distal to TGF-p ligand- receptor 
interactions.
A different pattern of growth factor responsiveness is 
apparent in the oncogene transfected cells. C-myc 
transfected cells have a a reduced response to TGF-p and 
an exaggerated response to EGF. Transfection of the mink 
lung epithelial cells with the normal ras protooncogene 
did not materially alter their response to TGF-B and EGF.
118
However, activated H-ras transfection virtually abolished 
the effect of both TGF-p and EGF.
Kelekar and Cole (103) immortalised early passage rat 
kidney cells with c-myc and H-ras and showed that the 
c-myc transfected cells responded to serum better than EGF 
and insulin alone and gave a maximal proliferative 
response to EGF and insulin. The results of Stern et al 
(104) are more similar to our own. They transfected 
Fischer rat 3T3 cells with myc and ras oncogenes and 
treated them with EGF, PDGF and TGF-p. Ras transfected 
cells were insensitive to all three growth factors and 
secreted EGF-like activity and TGF-B into cell culture
i
medium. Myc-transfected cells did not produce elevated 
levels of growth factors but did form colonies in soft 
agar in the presence of EGF, but not TGF-B and PDGF.
Balk et al (105) transfected chicken heart mesenchymal 
cells with v-myc and v-H-ras oncogenes and showed that 
cells transformed with v-myc were hypersensitive- to EGF 
whereas those transformed with v-H-ras were refactory to 
. EGF and brain fibroblast growth factor. Houck et al (106) 
showed that resistance to the growth inhibitory effect of 
TGF-B was induced by transfection of an activated H-ras 
oncogene into rat liver epithelial cells.
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In summary, this thesis presents data supportive of the 
hypothesis that a proportion of the cytostatic effect of 
a-iF on the human breast carcinoma cell line, ZR-75, is 
mediated by TGF-p, acting, in a way, like a second 
messenger. The bioactivity of TGF-p can be modulated by 
the presence of other exogenous growth factors (e.g. 
antagonised by EGF) and by oncogene transfection and 
activation. Therefore, if one supposes that in certain 
instances, 0£-IF will increase the rate of transcription of 
the TGF-B gene leading to an increase in activated TGF-B , 
an antiproliferative effect will only be seen if the 
cellular microenvironment and genotypic milieu are 
cooperative.
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